<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="fragilex" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">fragilex</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">FMR1</italic>-Related Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saul</surname>
            <given-names>Robert A</given-names>
          </name>
          <degrees>MD, FACMG</degrees>
          <aff>Greenwood Genetic Center<break/>Greenwood, South Carolina</aff>
          <email>rsaul@ggc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tarleton</surname>
            <given-names>Jack C</given-names>
          </name>
          <degrees>PhD, FACMG</degrees>
          <aff>Fullerton Genetics Center<break/>Asheville, North Carolina</aff>
          <email>jack.tarleton@msj.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>16</day>
          <month>6</month>
          <year>1998</year>
        </date>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="revised">
          <day>26</day>
          <month>4</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="foxp2-sl-dis" document-type="chapter"><italic toggle="yes">FOXP2-</italic>Related Speech and Language Disorders</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="xl-nystag" document-type="chapter"><italic toggle="yes">FRMD7</italic>-Related Infantile Nystagmus</related-object>
      <abstract id="fragilex.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">FMR1</italic>-related disorders include fragile X syndrome, fragile X-associated tremor/ataxia syndrome (FXTAS), and <italic toggle="yes">FMR1</italic>-related primary ovarian insufficiency (POI).</p>
          <p>Fragile X syndrome occurs in individuals with an <italic toggle="yes">FMR1</italic> full mutation or other loss-of-function variant and is nearly always characterized by moderate intellectual disability in affected males and mild intellectual disability in affected females. Because <italic toggle="yes">FMR1</italic> pathogenic variants are complex alterations involving non-classic gene-disrupting alterations (trinucleotide repeat expansion) and abnormal gene methylation, affected individuals occasionally have an atypical presentation with an IQ above 70, the traditional demarcation denoting intellectual disability (previously referred to as mental retardation). Males with an <italic toggle="yes">FMR1</italic> full mutation accompanied by aberrant methylation may have a characteristic appearance (large head, long face, prominent forehead and chin, protruding ears), connective tissue findings (joint laxity), and large testes after puberty. Behavioral abnormalities, sometimes including autism spectrum disorder, are common.</p>
          <p>FXTAS occurs in males (and some females) who have an <italic toggle="yes">FMR1</italic> premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor.</p>
          <p><italic toggle="yes">FMR1</italic>-related POI (age at cessation of menses &#x0003c;40 years) occurs in approximately 20% of females who have an <italic toggle="yes">FMR1</italic> premutation.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">FMR1</italic>-related disorders rests on the detection of an alteration in <italic toggle="yes">FMR1</italic>. More than 99% of individuals with fragile X syndrome have a loss-of-function variant of <italic toggle="yes">FMR1</italic> caused by an increased number of CGG trinucleotide repeats (typically &#x0003e;200) accompanied by aberrant methylation of <italic toggle="yes">FMR1</italic>. Other pathogenic variants within <italic toggle="yes">FMR1</italic> that cause fragile X syndrome include deletions and single-nucleotide variants. All individuals with FXTAS and <italic toggle="yes">FMR1</italic>-related POI have <italic toggle="yes">FMR1</italic> premutation trinucleotide repeats ranging from 55 to approximately 200. Both increased trinucleotide repeats and methylation changes in <italic toggle="yes">FMR1</italic> can be detected by molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Fragile X syndrome: early developmental intervention, special education (individual attention, small class size, and avoiding sudden change and excessive stimulation), and vocational training; individualized pharmacologic management of behavioral issues that significantly affect social interaction; routine treatment of medical problems. FXTAS: supportive care for gait disturbance and/or cognitive deficits. POI: reproductive endocrine evaluation for treatment and counseling for reproductive options.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Folic acid in individuals with poorly controlled seizures.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>All mothers of individuals with an <italic toggle="yes">FMR1</italic> full mutation (expansion &#x0003e;200 CGG trinucleotide repeats and abnormal methylation) are carriers of an <italic toggle="yes">FMR1</italic> pathogenic variant. Mothers and their female relatives who are premutation carriers are at increased risk for FXTAS and POI; those with a full mutation may have findings of fragile X syndrome. All are at increased risk of having offspring with fragile X syndrome, FXTAS, and POI. Males with premutations are at increased risk for FXTAS. Males with FXTAS will transmit their <italic toggle="yes">FMR1</italic> premutation expansion to none of their sons and to all of their daughters, who will be premutation carriers. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the diagnosis of an <italic toggle="yes">FMR1</italic>-related disorder has been confirmed in a family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="fragilex.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="fragilex.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_fragilex.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">FMR1</italic>-Related Disorders: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_fragilex.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Fragile X syndrome</p></list-item><list-item><p>Fragile X-associated tremor/ataxia syndrome (FXTAS)</p></list-item><list-item><p><italic toggle="yes">FMR1</italic>-related primary ovarian insufficiency</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="fragilex.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="fragilex.Diagnosis">
        <title>Diagnosis</title>
        <sec id="fragilex.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p><bold>Fragile X syndrome.</bold> A definite diagnosis of fragile X syndrome requires the presence of a loss-of-function variant in <italic toggle="yes">FMR1</italic>, usually in a male with moderate intellectual disability or a female with mild intellectual disability.</p>
          <p>Note: Because <italic toggle="yes">FMR1</italic> pathogenic variants are complex alterations involving non-classic gene-disrupting alterations (trinucleotide repeat expansion) and abnormal gene methylation, affected individuals occasionally have an atypical presentation with an IQ above 70, the traditional demarcation denoting intellectual disability.</p>
          <p>Affected individuals have normal growth and stature and no associated malformations.</p>
          <p><bold>Fragile X-associated tremor/ataxia syndrome (FXTAS)</bold> (see <xref ref-type="table" rid="fragilex.T.fxtas_major_and_minor_diagnos">Table 1</xref>)</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>A definite diagnosis of FXTAS</bold> requires the presence of a premutation in <italic toggle="yes">FMR1</italic> and white matter lesions on MRI in the middle cerebellar peduncles and/or brain stem (the major neuroradiologic sign) with either intention tremor or gait ataxia (the two major clinical signs).</p>
              <p>Other minor neuroradiologic criteria include MRI white matter lesions in the cerebral white matter or moderate to generalized atrophy.</p>
              <p>Other minor clinical criteria include parkinsonism, moderate to severe working memory deficits, or executive cognitive function deficits.</p>
            </list-item>
            <list-item>
              <p><bold>A probable diagnosis of FXTAS</bold> requires either one major neuroradiologic sign and one minor clinical sign or two major clinical signs.</p>
            </list-item>
            <list-item>
              <p><bold>A possible diagnosis of FXTAS</bold> is based on one minor neuroradiologic sign and one major clinical sign [<xref ref-type="bibr" rid="fragilex.REF.grigsby.2005">Grigsby et al 2005</xref>].</p>
            </list-item>
          </list>
          <table-wrap id="fragilex.T.fxtas_major_and_minor_diagnos" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>FXTAS: Major and Minor Diagnostic Criteria</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"/>
                  <th id="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Neuroradiologic Signs</th>
                  <th id="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Clinical Signs</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Major</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Premutation in <italic toggle="yes">FMR1</italic></p></list-item><list-item><p>White matter lesions on MRI in the middle cerebellar peduncles and/or brain stem</p></list-item></list>
</td>
                  <td headers="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Intention tremor</p></list-item><list-item><p>Gait ataxia</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Minor</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>MRI white matter lesions in the cerebral white matter</p></list-item><list-item><p>Moderate to generalized atrophy</p></list-item></list>
</td>
                  <td headers="hd_h_fragilex.T.fxtas_major_and_minor_diagnos_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Parkinsonism</p></list-item><list-item><p>Moderate to severe working memory deficits</p></list-item><list-item><p>Executive cognitive function deficits</p></list-item></list>
</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p><bold><italic toggle="yes">FMR1</italic>-related primary ovarian insufficiency (POI).</bold>
<italic toggle="yes">FMR1</italic>-related POI is defined as cessation of menses before age 40 years in a woman who has one <italic toggle="yes">FMR1</italic> allele with trinucleotide repeats from 55 to 200 (premutation). The earlier findings that alleles in the high normal and intermediate range conferred an increased risk for <italic toggle="yes">FMR1</italic>-related POI [<xref ref-type="bibr" rid="fragilex.REF.bretherick.2005.376">Bretherick et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.bodega.2006.952">Bodega et al 2006</xref>] were not supported by a recent more robust study [<xref ref-type="bibr" rid="fragilex.REF.bennett.2010.1335">Bennett et al 2010</xref>].</p>
        </sec>
        <sec id="fragilex.Testing">
          <title>Testing</title>
          <p><bold>Chromosome analysis.</bold> Chromosome analysis using modified culture techniques to induce fragile sites is no longer used for diagnosis of fragile X syndrome because it is less sensitive and more costly than molecular genetic testing (see <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>).</p>
          <p><bold>Protein testing.</bold> Although protein testing is not performed routinely in most clinical laboratory settings, a few laboratories provide assays that qualitatively measure the production of the protein product of <italic toggle="yes">FMR1</italic>, fragile X mental retardation protein 1 (FMRP) [<xref ref-type="bibr" rid="fragilex.REF.willemsen.1997.308">Willemsen et al 1997</xref>].</p>
          <p>Situations in which FMRP testing may be useful include screening of males with intellectual disability and characterization of cellular production of FMRP in males having unusual phenotypes. Because severity of the fragile X syndrome phenotype appears to correlate with FMRP expression in peripheral blood lymphocytes, assessment of FMRP production in some affected males has been proposed as a potential prognostic indicator of disease severity [<xref ref-type="bibr" rid="fragilex.REF.tassone.1999.250">Tassone et al 1999</xref>].</p>
          <sec id="fragilex.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">FMR1</italic> is the only gene in which mutation is known to cause <italic toggle="yes">FMR1</italic>-related disorders.</p>
            <p><bold>Allele sizes.</bold>
<italic toggle="yes">FMR1</italic> alleles are categorized according to the number of CGG trinucleotide repeats in exon 1 and the methylation status of the repeat region. However, the distinction between allele categories is not absolute and must be made by considering both family history and repeat instability. The boundary between intermediate and premutation categories listed below is not precise and caution is advised. See <xref ref-type="table" rid="fragilex.T.types_of_fmr1_repeat_expansio">Table 4</xref> for a summary of the types of <italic toggle="yes">FMR1</italic> alleles and clinical status of individuals with expanded alleles. See <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref> for detailed information on types of <italic toggle="yes">FMR1</italic> alleles and their behavior during transmission.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Normal alleles.</bold> Approximately 5-44 repeats</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Alleles of this size have no meiotic or mitotic instability and are transmitted without any increase or decrease in repeat number.</p>
                  </list-item>
                  <list-item>
                    <p>The population distribution of <italic toggle="yes">FMR1</italic> repeat alleles shows the highest percentage of individuals with approximately 29-31 repeats and smaller but significant percentages clustering around 20 and 40 repeats.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Intermediate alleles (also termed "gray zone" or &#x0201c;borderline&#x0201d;). Approximately 45-54 repeats</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Intermediate alleles do not cause fragile X syndrome. However, about 14% of intermediate alleles are unstable and may expand into the premutation range when transmitted by the mother [<xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al 2011</xref>]. They are not known to expand to full mutations; therefore, offspring are not at increased risk for fragile X syndrome.</p>
                  </list-item>
                  <list-item>
                    <p>Historically, the largest repeat included in the intermediate range has been 54; the use of 54 as the upper limit for normal alleles is a conservative estimate reflecting observations that transmission of alleles with 54 repeats or fewer from mothers to their offspring has not resulted in an affected individual to date. The conservative nature of the estimate also reflects potential imprecision (usually stated as &#x000b1;2-3 repeats) in laboratory measurement of repeat number during diagnostic testing; however, to date no transmission of alleles with 56 or fewer repeats is known to have resulted in an affected individual [<xref ref-type="bibr" rid="fragilex.REF.fernandezcarvajal.2009.306">Fernandez-Carvajal et al 2009</xref>].</p>
                    <p>Note: Clinical laboratories performing <italic toggle="yes">FMR1</italic> analysis typically state their estimated precision range when measuring intermediate alleles and usually report their estimates as &#x000b1;2-3 repeats. Thus, it may be prudent to consider reported test results with 55 repeats as potential premutations. If the repeat precision estimate is not on the laboratory report, the laboratory should be contacted in order to determine if a result should be considered as a potential premutation.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Premutation alleles.</bold> Approximately 55-200 repeats</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Alleles of this size are not associated with fragile X syndrome, but do convey increased risk for FXTAS and POI (<xref ref-type="table" rid="fragilex.T.types_of_fmr1_repeat_expansio">Table 4</xref>). Because of potential repeat instability upon transmission of premutation alleles, women with alleles in this range are considered to be at risk of having children affected with fragile X syndrome.</p>
                  </list-item>
                  <list-item>
                    <p><xref ref-type="bibr" rid="fragilex.REF.fernandezcarvajal.2009.306">Fernandez-Carvajal et al [2009]</xref> reported maternal transmission of a 56-repeat allele resulting in an offspring with a full mutation; thus, 56 is the smallest repeat known to expand to full mutation in a single transmission.</p>
                    <p>Note: The upper limit of the premutation range is sometimes noted as approximately 230. Both numbers (200 and 230) are estimates derived from Southern blot analysis, in which repeat size can only be roughly estimated.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Full-mutation alleles.</bold> More than 200 CGG repeats, with several hundred to several thousand repeats being typical and associated with aberrant hypermethylation of the <italic toggle="yes">FMR1</italic> promoter. Almost always, extensive somatic variation of repeat number is observed in a peripheral blood specimen of a patient with a full mutation. As a result, clinical laboratories may report this somatic variation as a range of several hundred repeats.</p>
              </list-item>
            </list>
            <p>See <xref ref-type="sec" rid="fragilex.References">Published Guidelines/Consensus Statements</xref>; see <xref ref-type="bibr" rid="fragilex.REF.amos_wilson.2008.2">Amos Wilson et al [2008]</xref>, <xref ref-type="bibr" rid="fragilex.REF.hawkins.2011.10">Hawkins et al [2011]</xref> on the availability of reference materials for clinical laboratories.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>
                  <bold>Targeted analysis for pathogenic variants</bold>
                </p>
                <list list-type="bullet">
                  <list-item>
                    <p><bold>Polymerase chain reaction (PCR)</bold> specific for the CGG trinucleotide repeat region of <italic toggle="yes">FMR1</italic> has high sensitivity for <italic toggle="yes">FMR1</italic> repeats in the normal and lower premutation range (typically &#x02264;100 to 120 repeats; varies by testing laboratory). However, traditional <italic toggle="yes">FMR1</italic>-specific PCR is less sensitive to larger premutations and fails to amplify full mutations. Newer methods promise to overcome these limitations (see <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
                  </list-item>
                  <list-item>
                    <p><bold>Southern blot analysis</bold> detects all <italic toggle="yes">FMR1</italic> alleles including normal, larger-sized premutations, and full mutations and in addition determines methylation status of the <italic toggle="yes">FMR1</italic> promoter region. Abnormal hypermethylation of <italic toggle="yes">FMR1</italic> is the cause of transcriptional silencing and is critical to assess for premutation and full mutation alleles.</p>
                    <p>Note: Although Southern blot analysis provides a low-resolution estimation of repeat number, traditional PCR plus Southern blot analysis has been the &#x0201c;gold standard&#x0201d; for <italic toggle="yes">FMR1</italic> molecular diagnosis. As newer and more sensitive PCR methods gain acceptance in diagnostic testing, the need for Southern blot analysis of every patient may decrease [<xref ref-type="bibr" rid="fragilex.REF.chen.2010.589">Chen et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.filipovicsadic.2010.399">Filipovic-Sadic et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.hantash.2010.162">Hantash et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.lyon.2010.505">Lyon et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.chen.2011.528">Chen et al 2011</xref>, <xref ref-type="bibr" rid="fragilex.REF.nahhas.2012.187">Nahhas et al 2012</xref>].</p>
                  </list-item>
                  <list-item>
                    <p><bold>AGG trinucleotide repeat genotyping.</bold> AGG genotyping is offered as a separate test to determine the number and location of AGG trinucleotide interruptions within the tract of CGG repeats of <italic toggle="yes">FMR1</italic>. The number and position of AGG trinucleotide repeats are known to be important in the overall stability of the CGG repeat sequence [<xref ref-type="bibr" rid="fragilex.REF.eichler.1994.88">Eichler et al 1994</xref>]. Recent results have linked the length of the uninterrupted 3&#x02019; CGG repeat length with expansion and suggest a minimum threshold for expansion risk [<xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al 2011</xref>]. The clinical usefulness of such testing awaits publication of the full study. This test is offered for female carriers of intermediate and small premutation alleles.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Methylation status</bold> can be assessed by PCR-based methods independent of measuring the number of CGG repeats</p>
              </list-item>
              <list-item>
                <p><bold>Sequence analysis.</bold> Very few individuals with fragile X syndrome have been identified with an intragenic <italic toggle="yes">FMR1</italic> pathogenic variant.</p>
              </list-item>
              <list-item>
                <p><bold>Deletion/duplication analysis.</bold> Fewer than 1% of individuals with fragile X syndrome have a partial or full deletion of <italic toggle="yes">FMR1</italic> (reviewed in <xref ref-type="bibr" rid="fragilex.REF.hammond.1997.430">Hammond et al [1997]</xref>). Lack of amplification by PCR prior to sequence analysis can suggest a putative exon or whole-gene deletion on the X chromosome in affected males; confirmation may require additional testing by deletion/duplication analysis. However, deletions not located in the repeat region of the gene may be missed in males on routine clinical testing by PCR for the trinucleotide repeat expansion. Deletions are typically detected in <italic toggle="yes">FMR1</italic> as a secondary finding when the trinucleotide repeat region is being interrogated by Southern blot analysis, FISH, or other method (see <xref ref-type="table" rid="fragilex.T.summary_of_molecular_genetic">Table 2</xref>, footnote 4). Therefore, it is likely that <italic toggle="yes">FMR1</italic> deletions downstream of the repeat region, as well as other gene rearrangements, are under ascertained. Nevertheless, both small deletions near the repeat region in exon 1 and large-scale deletions that completely remove <italic toggle="yes">FMR1</italic> continue to be reported in the literature.</p>
              </list-item>
            </list>
            <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v19/n9/full/ejhg201155a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="fragilex.REF.jacquemont.2011.19">Jacquemont et al 2011</xref>] for information on test characteristics including sensitivity and specificity.</p>
            <table-wrap id="fragilex.T.summary_of_molecular_genetic" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">FMR1</italic>-Related Disorders</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_1" rowspan="7" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">FMR1</italic>
                    </td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_2" rowspan="3" valign="middle" align="left" colspan="1">Targeted analysis for pathogenic variants</td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><bold>PCR.</bold> CGG expansion in <italic toggle="yes">FMR1</italic> (allele sizes in the normal and lower premutation range)&#x000a0;<sup>4,&#x000a0;5</sup></td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" rowspan="2" valign="middle" align="left" colspan="1">&#x0003e;99%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1"><bold>Southern blot.</bold> CGG expansion in <italic toggle="yes">FMR1</italic> (all repeat ranges); methylation status&#x000a0;<sup>4,&#x000a0;6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1"><bold>AGG trinucleotide repeat genotyping.</bold> Number and position of AGG trinucleotide repeats that may interrupt the CGG repeats of <italic toggle="yes">FMR1</italic>&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">100% of alleles of this structure&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Methylation analysis</td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Methylation of <italic toggle="yes">FMR1</italic> promoter region&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">100% of alleles with this modification</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">FISH</td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Large (partial- or whole-gene) <italic toggle="yes">FMR1</italic> deletions</td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Large (partial- or whole-gene) <italic toggle="yes">FMR1</italic> deletions/duplications</td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">FMR1</italic> sequence variants&#x000a0;<sup>4,&#x000a0;5</sup></td>
                    <td headers="hd_h_fragilex.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="fragilex.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="fragilex" object-id="fragilex.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="fragilex.TF.2.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="fragilex.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="fragilex.TF.2.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="fragilex.TF.2.4">
                  <label>4. </label>
                  <p>Sequence analysis, targeted analysis for pathogenic variants using PCR, and in some instances Southern blot analysis cannot detect an exon or whole-gene deletion on the X chromosome in carrier females.</p>
                </fn>
                <fn id="fragilex.TF.2.5">
                  <label>5. </label>
                  <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative partial or whole-gene deletion on the X chromosome in affected males; confirmation may require additional testing by deletion/duplication analysis.</p>
                </fn>
                <fn id="fragilex.TF.2.6">
                  <label>6. </label>
                  <p>As newer and more sensitive PCR methods gain acceptance in diagnostic testing, the need for Southern blot analysis may decrease [<xref ref-type="bibr" rid="fragilex.REF.chen.2010.589">Chen et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.filipovicsadic.2010.399">Filipovic-Sadic et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.hantash.2010.162">Hantash et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.lyon.2010.505">Lyon et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.chen.2011.528">Chen et al 2011</xref>, <xref ref-type="bibr" rid="fragilex.REF.nahhas.2012.187">Nahhas et al 2012</xref>].</p>
                </fn>
                <fn id="fragilex.TF.2.7">
                  <label>7. </label>
                  <p>This test is offered for female carriers of intermediate and small premutation alleles to assess risk of expansion upon transmission. The clinical usefulness of such testing awaits publication of the full study. See <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>.</p>
                </fn>
                <fn id="fragilex.TF.2.8">
                  <label>8. </label>
                  <p>Methylation status can be determined by either Southern blot or methylation-specific PCR; the latter may offer a more rapid test turnaround time [<xref ref-type="bibr" rid="fragilex.REF.das.1997.151">Das et al 1997</xref>, <xref ref-type="bibr" rid="fragilex.REF.weinh_usel.2001.450">Weinh&#x000e4;usel &#x00026; Haas 2001</xref>, <xref ref-type="bibr" rid="fragilex.REF.nygren.2008.496">Nygren et al 2008</xref>, <xref ref-type="bibr" rid="fragilex.REF.coffee.2009">Coffee 2009</xref>, <xref ref-type="bibr" rid="fragilex.REF.chen.2011.528">Chen et al 2011</xref>].</p>
                </fn>
                <fn id="fragilex.TF.2.9">
                  <label>9. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="fragilex.TF.2.10">
                  <label>10. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Interpretation of test results.</bold> If the clinical phenotype is consistent with fragile X syndrome and molecular genetic testing of DNA extracted from leukocytes is normal, molecular genetic testing of a second tissue type (e.g., skin fibroblasts) should be considered [<xref ref-type="bibr" rid="fragilex.REF.mackenzie.2006.39">MacKenzie et al 2006</xref>].</p>
          </sec>
        </sec>
        <sec id="fragilex.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>Confirming/establishing the diagnosis.</bold> Molecular genetic testing is appropriate for the following (see <xref ref-type="fig" rid="fragilex.F1">Figure 1</xref>. Testing algorithm):</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals of either sex with intellectual disability, developmental delay, or autism, especially if they have any of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Any physical or behavioral characteristics of fragile X syndrome</p>
                </list-item>
                <list-item>
                  <p>A family history of fragile X syndrome</p>
                </list-item>
                <list-item>
                  <p>Male or female relatives with undiagnosed intellectual disability</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Individuals who have a cytogenetic fragile X test result that is discordant with their phenotype, including:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Those who have a strong clinical indication (including risk of being a carrier) and who have had a normal or ambiguous cytogenetic fragile X test result; and</p>
                </list-item>
                <list-item>
                  <p>Those with an atypical phenotype who have had a positive cytogenetic fragile X test result</p>
                  <p>Note: Chromosome analysis using modified culture techniques to induce fragile sites (i.e., cytogenetic fragile X test) is no longer used for diagnosis of fragile X syndrome because it is less sensitive and more costly than molecular genetic testing.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Males and females older than age 50 years who have progressive cerebellar ataxia and intention tremor with a positive family history of <italic toggle="yes">FMR1</italic>-related disorders in whom other common causes of ataxia have been excluded (see <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Ataxia Overview</related-object>)</p>
            </list-item>
            <list-item>
              <p>Women with unexplained POI [<xref ref-type="bibr" rid="fragilex.REF.corrigan.2005.1508">Corrigan et al 2005</xref>]</p>
            </list-item>
          </list>
          <p>
            <bold>Molecular genetic laboratory testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing for fragile X syndrome must include method(s) to detect all types of <italic toggle="yes">FMR1</italic> allele expansions; typically, these are PCR and Southern blot analysis. When PCR detects one normal allele in a male or two in a female, Southern blot analysis may not always be indicated. Southern blot, or another method to detect hypermethylation, should be performed for premutations and full mutations detected by PCR.</p>
              <list list-type="bullet">
                <list-item>
                  <p>For intermediate and small premutation alleles in carrier females, AGG trinucleotide genotyping may be useful to assess risk of allele expansion upon transmission.</p>
                </list-item>
                <list-item>
                  <p>Rarely, in individuals who have cellular mosaicism for the <italic toggle="yes">FMR1</italic> repeat PCR may give a false negative result because it cannot detect mosaicism for larger premutation and full-mutation alleles [<xref ref-type="bibr" rid="fragilex.REF.orrico.1998.341">Orrico et al 1998</xref>, <xref ref-type="bibr" rid="fragilex.REF.schmucker.1999.221">Schmucker &#x00026; Seidel 1999</xref>]. Southern blot analysis detects these complex alterations in most cases.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>FISH or deletion/duplication analysis should be used if PCR fails to detect the CGG repeats in a male or in female relatives of a proband known to have an <italic toggle="yes">FMR1</italic> deletion.</p>
            </list-item>
            <list-item>
              <p>Sequence analysis is very rarely needed. Very few affected individuals have been identified with a pathogenic variant outside of the CGG repeats.</p>
            </list-item>
          </list>
          <p><bold>Clarification of the genetic status of women</bold> seeking reproductive counseling who have a family history of <italic toggle="yes">FMR1</italic>-related disorders requires prior confirmation of the presence of an expanded (or altered) <italic toggle="yes">FMR1</italic> allele in the family or the presence of undiagnosed intellectual disability.</p>
          <p>Note: (1) Female carriers are heterozygotes for this X-linked disorder and may develop clinical findings related to the disorder; i.e., intellectual disability in full-mutation carriers, fragile X-associated tremor ataxia syndrome and primary ovarian insufficiency (POI) in premutation carriers. (2) Identification of female carriers requires appropriate molecular genetic testing to identify their status.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members (male relatives at risk for FXTAS and female relatives at risk for POI) requires prior identification of an expanded (or altered) <italic toggle="yes">FMR1</italic> allele in the family.</p>
          <p><bold>Prenatal diagnosis</bold> for at-risk pregnancies requires prior confirmation of the presence of an expanded (or altered) <italic toggle="yes">FMR1</italic> allele in the family.</p>
          <p>Note: Results from chorionic villus sampling (CVS) testing must be interpreted with caution because often the methylation status of <italic toggle="yes">FMR1</italic> is not yet established in chorionic villi at the time of sampling. CVS, while a standard technique for prenatal diagnosis, may lead to a situation in which follow-up amniocentesis is necessary to resolve an ambiguous result.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies requires prior confirmation of the presence of an expanded (or altered) <italic toggle="yes">FMR1</italic> allele in the family.</p>
        </sec>
      </sec>
      <sec id="fragilex.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="fragilex.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Males with full-mutation alleles (fragile X syndrome).</bold> The phenotypic features of males with a full mutation and, hence, the fragile X syndrome, vary in relation to puberty (see <bold>Clinical features in males with fragile X syndrome</bold>).</p>
          <p>Prepubertal males tend to have normal growth but large occipitofrontal head circumference (&#x0003e;50th percentile). Hypotonia, gastroesophageal reflux, and recurrent otitis media are problems in infancy that require medical attention [<xref ref-type="bibr" rid="fragilex.REF.hagerman.2002.278">Hagerman &#x00026; Hagerman 2002</xref>]. Delayed attainment of motor milestones and speech is apparent in the first several years of life. Other physical features not readily recognizable in the preschool-age child become more obvious with age. These involve the craniofacies (long face, prominent forehead, large ears, and prominent jaw) and genitalia (macro-orchidism), and abnormal temperament (hyperactivity, hand flapping, hand biting, temper tantrums, and occasionally autism).</p>
          <p>Behaviors in postpubertal males with fragile X syndrome often include tactile defensiveness, poor eye contact, perseverative speech, problems in impulse control, and distractibility. The behaviors tend to become more obvious over time. The comorbid diagnosis of autism occurs in nearly 25% of affected individuals [<xref ref-type="bibr" rid="fragilex.REF.hatton.2006.1804">Hatton et al 2006</xref>].</p>
          <p>Note: Recent evidence suggests an increased risk for autism spectrum disorder and/or attention deficit disorder in premutation carriers as well [<xref ref-type="bibr" rid="fragilex.REF.farzin.2006.s137">Farzin et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.hagerman.2009.378">Hagerman et al 2009</xref>].</p>
          <p>Ophthalmologic (strabismus), orthopedic (joint laxity), cardiac (mitral valve prolapse), and cutaneous (excess softness and smoothness) abnormalities have also been noted. Except for the strabismus, these issues typically do not require significant intervention.</p>
          <p>Periventricular heterotopia and other neuroradiologic abnormalities [<xref ref-type="bibr" rid="fragilex.REF.moro.2006.713">Moro et al 2006</xref>] are consistent with abnormal neuronal migration and development suggested by the metabotropic glutamate receptor (mGluR) theory of fragile X intellectual disability (see <xref ref-type="sec" rid="fragilex.Molecular_Genetics">Molecular Genetics</xref>).</p>
          <p><bold>Clinical features in males with fragile X syndrome</bold> (adapted from <xref ref-type="bibr" rid="fragilex.REF.tarleton.1993.169">Tarleton &#x00026; Saul [1993]</xref>)</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Delayed developmental milestones</bold> (usual age of attainment in boys)</p>
              <list list-type="bullet">
                <list-item>
                  <p>Sit alone (10 months)</p>
                </list-item>
                <list-item>
                  <p>Walk (20.6 months)</p>
                </list-item>
                <list-item>
                  <p>First clear words (20 months)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Prepubertal features</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Developmental delay, especially speech</p>
                </list-item>
                <list-item>
                  <p>Abnormal temperament: tantrums, hyperactivity, autism</p>
                </list-item>
                <list-item>
                  <p>Intellectual disability: IQ 30-50</p>
                </list-item>
                <list-item>
                  <p>Abnormal craniofacies: long face, prominent forehead, large ears, prominent jaw</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Postpubertal features</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Macro-orchidism</p>
                </list-item>
                <list-item>
                  <p>Abnormal behavior: shyness, gaze aversion</p>
                </list-item>
                <list-item>
                  <p>Ophthalmologic: strabismus</p>
                </list-item>
                <list-item>
                  <p>Orthopedic: joint hyperextensibility, pes planus</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Other features</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Cardiac: mitral valve prolapse, aortic root dilatation</p>
                </list-item>
                <list-item>
                  <p>Dermatologic: usually soft and smooth skin</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Females heterozygous for full-mutation alleles (fragile X syndrome).</bold> The physical and behavioral features seen in males with fragile X syndrome have been reported in females heterozygous for the full mutation, but with lower frequency and milder involvement.</p>
          <p><bold>Fragile X-associated tremor/ataxia syndrome (FXTAS)</bold> is characterized by late-onset progressive cerebellar ataxia and intention tremor in persons who have an <italic toggle="yes">FMR1</italic> premutation [<xref ref-type="bibr" rid="fragilex.REF.jacquemont.2004.460">Jacquemont et al 2004</xref>, <xref ref-type="bibr" rid="fragilex.REF.jacquemont.2006.804">Jacquemont et al 2006</xref>]. Other neurologic findings include short-term memory loss, executive function deficits, cognitive decline, dementia, parkinsonism, peripheral neuropathy, lower-limb proximal muscle weakness, and autonomic dysfunction [<xref ref-type="bibr" rid="fragilex.REF.loesch.2005.326">Loesch et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.bacalman.2006.87">Bacalman et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.grigsby.2006.227">Grigsby et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.louis.2006.420">Louis et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.mcconkierosell.2007.593">McConkie-Rosell et al 2007</xref>, <xref ref-type="bibr" rid="fragilex.REF.kogan.2008.859">Kogan et al 2008</xref>, <xref ref-type="bibr" rid="fragilex.REF.hunter.2009.79">Hunter et al 2009</xref>].</p>
          <p>Both males and females with a premutation are at increased risk for FXTAS. The prevalence of FXTAS is estimated at approximately 40% to 45% overall for males with premutations who are older than age 50 years [<xref ref-type="bibr" rid="fragilex.REF.grigsby.2005">Grigsby et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.jacquemont.2006.804">Jacquemont et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.rodriguezrevenga.2009.1359">Rodriguez-Revenga et al 2009</xref>]. Penetrance in males is age related (see <xref ref-type="table" rid="fragilex.T.risk_for_fxtas_by_age_in_male">Table 3</xref>). FXTAS occurs in both males and female premutation carriers, but the penetrance in individuals older than age 50 years is lower in females (16.5%) than in males (45.5%) [<xref ref-type="bibr" rid="fragilex.REF.rodriguezrevenga.2009.1359">Rodriguez-Revenga et al 2009</xref>].</p>
          <table-wrap id="fragilex.T.risk_for_fxtas_by_age_in_male" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Risk for FXTAS by Age in Males with an <italic toggle="yes">FMR1</italic> Premutation</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Age in Years</th>
                  <th id="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Risk</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">50-59</td>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">17%</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">60-69</td>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">38%</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">70-79</td>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">47%</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x02265;80</td>
                  <td headers="hd_h_fragilex.T.risk_for_fxtas_by_age_in_male_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">75%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Adapted from <xref ref-type="bibr" rid="fragilex.REF.grigsby.2005">Grigsby et al [2005]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>While FXTAS is more difficult to ascertain in females because of milder clinical presentation, prevalence estimates range from approximately 8% to 16.5% of female premutation carriers [<xref ref-type="bibr" rid="fragilex.REF.coffey.2008.1009">Coffey et al 2008</xref>, <xref ref-type="bibr" rid="fragilex.REF.rodriguezrevenga.2009.1359">Rodriguez-Revenga et al 2009</xref>].</p>
          <p>Increasing premutation repeat lengths are correlated to increasing likelihood of developing FXTAS [<xref ref-type="bibr" rid="fragilex.REF.tassone.2007.566">Tassone et al 2007</xref>, <xref ref-type="bibr" rid="fragilex.REF.leehey.2008.1397">Leehey et al 2008</xref>].</p>
          <p>A retrospective longitudinal review of 55 males with premutations provides early natural history information of FXTAS [<xref ref-type="bibr" rid="fragilex.REF.leehey.2007.203">Leehey et al 2007</xref>]. The first sign to appear is usually tremor at approximately age 60 years. Ataxia tends to develop two years later, leading to increased tendency to fall and subsequent dependence on walking aids. Life expectancy after onset of symptoms ranged from five to 25 years.</p>
          <p>Neuroradiologic signs (decreased cerebellar volume, increased ventricular volume, and increased white matter hyperdensity) appear to correlate with premutation CGG repeat length [<xref ref-type="bibr" rid="fragilex.REF.cohen.2006.1426">Cohen et al 2006</xref>].</p>
          <p><bold><italic toggle="yes">FMR1</italic>-related primary ovarian insufficiency (POI),</bold> defined as cessation of menses before age 40 years, has been observed in carriers of premutation alleles [<xref ref-type="bibr" rid="fragilex.REF.murray.1999.1217">Murray et al 1999</xref>, <xref ref-type="bibr" rid="fragilex.REF.uzielli.1999.300">Uzielli et al 1999</xref>, <xref ref-type="bibr" rid="fragilex.REF.hundscheid.2000.413">Hundscheid et al 2000</xref>, <xref ref-type="bibr" rid="fragilex.REF.bussani.2004.189">Bussani et al 2004</xref>, <xref ref-type="bibr" rid="fragilex.REF.machadoferreira_mdo.2004.237">Machado-Ferreira Mdo et al 2004</xref>, <xref ref-type="bibr" rid="fragilex.REF.mcconkierosell.2007.593">McConkie-Rosell et al 2007</xref>]. Ovarian failure has occurred as early as age 11 years. The diagnosis of POI does not eliminate the possibility of subsequent conception. A premutation carrier woman had a child with fragile X syndrome after her diagnosis with POI [<xref ref-type="bibr" rid="fragilex.REF.corrigan.2005.1508">Corrigan et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.nelson.2005.1327">Nelson et al 2005</xref>]. It is estimated that 5%-10% of women may conceive after the diagnosis of POI is established [<xref ref-type="bibr" rid="fragilex.REF.nelson.2005.1327">Nelson et al 2005</xref>]. See <xref ref-type="bibr" rid="fragilex.REF.sullivan.2011.299">Sullivan et al [2011]</xref> for a review.</p>
          <p>The earlier findings that alleles in the high normal and intermediate range conferred an increased risk for <italic toggle="yes">FMR1</italic>-related POI [<xref ref-type="bibr" rid="fragilex.REF.bretherick.2005.376">Bretherick et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.bodega.2006.952">Bodega et al 2006</xref>] were not supported by a recent more robust study [<xref ref-type="bibr" rid="fragilex.REF.bennett.2010.1335">Bennett et al 2010</xref>]. Currently, no consensus exists for estimating an absolute risk for POI when a woman has high normal or intermediate repeat alleles. <xref ref-type="bibr" rid="fragilex.REF.sherman.2005">Sherman [2005]</xref> concluded that the risk for POI was 21% (estimates ranged from 15% to 27% in various studies) in premutation carriers, compared to a 1% background risk. In this review an odds ratio of 2.5 was estimated for intermediate repeat sizes of 41-58 [<xref ref-type="bibr" rid="fragilex.REF.wittenberger.2007.456">Wittenberger et al 2007</xref>]. (See <xref ref-type="sec" rid="fragilex.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>, <bold>Premutation</bold> for additional risk estimates.)</p>
          <p><xref ref-type="bibr" rid="fragilex.REF.sullivan.2005.402">Sullivan et al [2005]</xref> suggest that variation in the age at menopause in the general population may be related to <italic toggle="yes">FMR1</italic> CGG repeat size below 80, a finding further supported by data from <xref ref-type="bibr" rid="fragilex.REF.ennis.2006.253">Ennis et al [2006]</xref>. A significant increase of alleles in the 35 to 54 range was found in women with POI [<xref ref-type="bibr" rid="fragilex.REF.bretherick.2005.376">Bretherick et al 2005</xref>]. In all three studies, larger premutations (&#x0003e;80 CGG repeats) carried lower risk for POI. <xref ref-type="bibr" rid="fragilex.REF.hunter.2008.553">Hunter et al [2008]</xref> suggested that other factors in addition to CGG repeat size affect the age at menopause; an additional study with over 360 women failed to demonstrate an increased risk for POI for women with alleles in the high normal and intermediate range (35-58 repeats) [<xref ref-type="bibr" rid="fragilex.REF.bennett.2010.1335">Bennett et al 2010</xref>].</p>
          <p>Women with full-mutation alleles are not at increased risk for POI.</p>
        </sec>
        <sec id="fragilex.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The phenotype of males with an <italic toggle="yes">FMR1</italic> pathogenic variant depends almost entirely on the nature of the variant; the phenotype of females with an <italic toggle="yes">FMR1</italic> pathogenic variant depends on both the nature of the <italic toggle="yes">FMR1</italic> variant and random X-chromosome inactivation (see <xref ref-type="table" rid="fragilex.T.types_of_fmr1_repeat_expansio">Table 4</xref>).</p>
          <table-wrap id="fragilex.T.types_of_fmr1_repeat_expansio" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Types of <italic toggle="yes">FMR1</italic> Repeat Expansion Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1">Variant Type</th>
                  <th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2">Number of CGG Trinucleotide Repeats</th>
                  <th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3">Methylation Status of <italic toggle="yes">FMR1</italic></th>
                  <th id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Clinical Status</th>
                </tr>
                <tr>
                  <th headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4" id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Male</th>
                  <th headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4" id="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Female</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Premutation</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~55-200</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unmethylated</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">At risk for FXTAS&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">At risk for POI and FXTAS&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Full mutation</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;200</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Completely methylated</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">100% with MR</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~50% with ID, ~50% normal intellect</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Repeat size mosaicism</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Varies between premutation and full mutation in different cell lines</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Partial: unmethylated in the premutation cell line; methylated in the full-mutation cell line</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" rowspan="2" valign="middle" align="left" colspan="1">Nearly 100% affected with ID; may be higher functioning&#x000a0;<sup>2</sup> than males with full mutation</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_2" rowspan="3" valign="middle" align="left" colspan="1">Highly variable: ranges from normal intellect to affected</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Methylation mosaicism</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;200</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Partial: mixture of methylated and unmethylated cell lines</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Unmethylated full mutation</bold>
                  </td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;200</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unmethylated</td>
                  <td headers="hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_1_4 hd_h_fragilex.T.types_of_fmr1_repeat_expansio_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Nearly all have ID but often have high-functioning MR to low-normal intellect</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>ID=intellectual disability</p>
              </fn>
              <fn id="fragilex.TF.4.1">
                <label>1. </label>
                <p>Both males and females with premutations and manifestations of some symptoms of fragile X syndrome have been reported [<xref ref-type="bibr" rid="fragilex.REF.riddle.1998.590">Riddle et al 1998</xref>, <xref ref-type="bibr" rid="fragilex.REF.bourgeois.2009.852">Bourgeois et al 2009</xref>, <xref ref-type="bibr" rid="fragilex.REF.hunter.2009.79">Hunter et al 2009</xref>, <xref ref-type="bibr" rid="fragilex.REF.chonchaiya.2010.38">Chonchaiya et al 2010</xref>].</p>
              </fn>
              <fn id="fragilex.TF.4.2">
                <label>2. </label>
                <p><italic toggle="yes">FMR1</italic> pathogenic variants are complex alterations involving non-classic gene-inactivating variants (trinucleotide repeat expansion) and abnormal gene methylation. This complexity at the gene level affects production of the <italic toggle="yes">FMR1</italic> protein and may result in an atypical presentation in which affected individuals occasionally have an IQ above 70, the traditional demarcation denoting intellectual disability (previously referred to as mental retardation).</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Premutation.</bold> Males and females who have a fragile X premutation have normal intellect and appearance. As noted in <xref ref-type="table" rid="fragilex.T.types_of_fmr1_repeat_expansio">Table 4</xref>, footnote 1, a few individuals with a premutation have subtle intellectual or behavioral symptoms including learning difficulties or social anxiety. The difficulties are usually not socially debilitating, and these individuals may still marry and have children.</p>
          <p>It is estimated that 21% of premutation carriers develop POI [<xref ref-type="bibr" rid="fragilex.REF.sherman.2005">Sherman 2005</xref>]. The odds ratios for POI in premutation carrier females increase with increasing repeat sizes [<xref ref-type="bibr" rid="fragilex.REF.sherman.2005">Sherman 2005</xref>] (see <xref ref-type="table" rid="fragilex.T.odds_ratios_for_poi_by_premut">Table 5</xref>). Although the numbers vary slightly, other studies confirm that these increased risks tend to plateau above 80-100 repeats [<xref ref-type="bibr" rid="fragilex.REF.bodega.2006.952">Bodega et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.ennis.2006.253">Ennis et al 2006</xref>].</p>
          <table-wrap id="fragilex.T.odds_ratios_for_poi_by_premut" orientation="portrait" position="anchor">
            <label>Table 5. </label>
            <caption>
              <p>Odds Ratios for POI by Premutation Size</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Premutation Size in CGG Repeats</th>
                  <th id="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Odds Ratio for POI</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">59-79</td>
                  <td headers="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6.9</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">80-99</td>
                  <td headers="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">25.1</td>
                </tr>
                <tr>
                  <td headers="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x0003e;100</td>
                  <td headers="hd_h_fragilex.T.odds_ratios_for_poi_by_premut_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">16.4</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>
                  <xref ref-type="bibr" rid="fragilex.REF.sherman.2005">Sherman [2005]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Full mutation.</bold> Males who have a full <italic toggle="yes">FMR1</italic> mutation generally have moderate to severe intellectual disability and may or may not have a distinctive appearance.</p>
          <p>Approximately 50% of females who have a full <italic toggle="yes">FMR1</italic> mutation are intellectually disabled; however, they are usually less severely affected than males with a full mutation. Conversely, approximately 50% of females who are heterozygous for the full mutation are intellectually normal. The variability among females is believed to result from the ratio in the brain of active X chromosomes with the <italic toggle="yes">FMR1</italic> full mutation to inactive X chromosomes with the normal <italic toggle="yes">FMR1</italic> allele.</p>
          <p><bold>Mosaicism.</bold> Mosaicism is present in approximately 15%-20% of individuals with <italic toggle="yes">FMR1</italic> variants. Such mosaicism may be (1) "repeat size mosaicism," in which both full mutations and premutations are present (also termed "full-mutation / premutation mosaicism"), or (2) methylation mosaicism, in which full mutations have varying degrees of methylation.</p>
          <p>Although some data suggest that individuals with repeat size mosaicism or methylation mosaicism perform at a higher intellectual level than those with completely methylated full mutations, such individuals are usually intellectually disabled.</p>
          <p>Rarely, individuals with methylation mosaicism or completely unmethylated full mutations and normal intellect have been reported. The milder phenotype appears to be related to FMRP production arising from transcription of unmethylated alleles [<xref ref-type="bibr" rid="fragilex.REF.tassone.1999.250">Tassone et al 1999</xref>]. Presumably, these individuals produce at least some FMRP because <italic toggle="yes">FMR1</italic> is unmethylated. The existence of these exceptional individuals suggests that repeat expansion and methylation of the gene are not absolutely coupled.</p>
        </sec>
        <sec id="fragilex.Anticipation">
          <title>Anticipation</title>
          <p>Fragile X syndrome is a trinucleotide repeat disorder that may demonstrate anticipation in some families. Typically, anticipation occurs when less severely affected premutation or mosaic mutation carriers transmit unstable <italic toggle="yes">FMR1</italic> alleles to their offspring (e.g., transmission from a grandfather who carries a premutation to his daughter, whose premutation expands into a full mutation when she transmits it to her son, who has intellectual disability as a result). However, the anticipation found in families with members affected with fragile X syndrome is not classic, as is that found in, for example, <related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter">myotonic dystrophy type 1</related-object>. Many families transmit premutation <italic toggle="yes">FMR1</italic> alleles for generations with little or no presentation of clinical symptoms until a full mutation is produced, resulting in an affected individual.</p>
        </sec>
        <sec id="fragilex.Nomenclature">
          <title>Nomenclature</title>
          <p><italic toggle="yes">FMR1</italic>-related primary ovarian insufficiency is also referred to as <italic toggle="yes">FMR1</italic>-related premature ovarian failure.</p>
          <p>Fragile X syndrome is also refrerred to as FXS, fragile X mental retardation, marker X syndrome, or Martin-Bell syndrome.</p>
        </sec>
        <sec id="fragilex.Prevalence">
          <title>Prevalence</title>
          <p><bold>Fragile X syndrome.</bold> Prevalence estimates of males with fragile X syndrome have been revised downward since the isolation of <italic toggle="yes">FMR1</italic> in 1991. Original estimates of 80:100,000 males affected with the syndrome (often still quoted in the fragile X literature) were based on the cytogenetic detection of the fragile site FRAXA for confirmation of the diagnosis of fragile X syndrome in males with intellectual disability. Individuals with intellectual disability coincidentally having other chromosomal fragile sites near FRAXA (e.g., FRAXD, FRAXE, and FRAXF) were likely included in the initial estimates. (Cytogenetic differentiation of these fragile sites is difficult because they are located in close proximity in the Xq27-q28 region.) More recent studies using molecular genetic testing of <italic toggle="yes">FMR1</italic> have estimated a prevalence of 16 to 25:100,000 males affected with the fragile X syndrome (using intellectual disability as the hallmark clinical finding) [<xref ref-type="bibr" rid="fragilex.REF.de_vries.1997.660">de Vries et al 1997</xref>].</p>
          <p>A blinded study of 10,046 newborn males in Taiwan yielded one male with a full mutation and estimated prevalence of 1:1,674 for males with a premutation and 1:143 for intermediate (45-54) alleles [<xref ref-type="bibr" rid="fragilex.REF.tzeng.2005.37">Tzeng et al 2005</xref>]. In an analysis of 36,124 newborn males, <xref ref-type="bibr" rid="fragilex.REF.coffee.2009.503">Coffee et al [2009]</xref> determined that the incidence of a full mutation (and hence, fragile X syndrome) was 1:5164.</p>
          <p>The prevalence of females affected with fragile X syndrome is presumed to be approximately one half the male prevalence. A population-based prevalence study of affected African American males revealed a higher estimate (39:100,000; 95% CI, 19-78:100,000) than reported previously for whites, although confidence intervals overlap those estimated for whites from this and other studies (27:100,000; 95% CI, 13-54:100,000) [<xref ref-type="bibr" rid="fragilex.REF.crawford.2002.226">Crawford et al 2002</xref>].</p>
          <p><bold>Unaffected female <italic toggle="yes">FMR1</italic> premutation carriers.</bold> The prevalence of females who are unaffected <italic toggle="yes">FMR1</italic> premutation carriers is high:</p>
          <list list-type="bullet">
            <list-item>
              <p>In 10,624 French-Canadian women, 41 were found to have an <italic toggle="yes">FMR1</italic> premutation, representing a prevalence of 1:259 [386:100,000; 95% CI, 1:373-1:198 (268-505:100,000)] [<xref ref-type="bibr" rid="fragilex.REF.rousseau.1995.1006">Rousseau et al 1995</xref>].</p>
            </list-item>
            <list-item>
              <p>In 14,334 Israeli women of child-bearing age, 127 were found to have CGG repeats greater than 54, including three asymptomatic women with full mutations, representing a prevalence of 1:113 (885:100,000) [<xref ref-type="bibr" rid="fragilex.REF.toledanoalhadef.2001.351">Toledano-Alhadef et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>In nearly 2,300 women from the United States, the prevalence of premutations was 1:382 (262:100,000) and of intermediate alleles, 1:143 (699:100,000) [<xref ref-type="bibr" rid="fragilex.REF.cronister.2005.246">Cronister et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>In the largest study to date from a laboratory database of more than 59,000 tests, the overall female carrier frequency was 1.3% (0.61% for full mutation, 1.7% for a premutation) [<xref ref-type="bibr" rid="fragilex.REF.strom.2007.46">Strom et al 2007</xref>].</p>
            </list-item>
          </list>
          <p><bold>Females with <italic toggle="yes">FMR1</italic>-related POI.</bold> The <italic toggle="yes">FMR1</italic> premutation accounts for 4%-6% of all cases of 46,XX POI [reviewed in <xref ref-type="bibr" rid="fragilex.REF.sullivan.2011.299">Sullivan et al 2011</xref>].</p>
          <p><bold>Males with FXTAS.</bold> An estimated 2%-4% of men with adult-onset cerebellar ataxia who represent simplex cases (i.e., a single occurrence in a family) have a premutation in <italic toggle="yes">FMR1</italic> [<xref ref-type="bibr" rid="fragilex.REF.brussino.2005.145">Brussino et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.cellini.2006.1135">Cellini et al 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="fragilex.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than fragile X syndrome, FXTAS, and POI are known to be associated with pathogenic variants in <italic toggle="yes">FMR1</italic>.</p>
        <p>However, preliminary studies of the correlation of <italic toggle="yes">FMR1</italic> allele size variations in the normal and premutation range suggest a possible relationship to mild intellectual disability in females [<xref ref-type="bibr" rid="fragilex.REF.allen.2005.435">Allen et al 2005</xref>] and males [<xref ref-type="bibr" rid="fragilex.REF.loat.2006.555">Loat et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.hagerman.2009.378">Hagerman et al 2009</xref>]. A study of 110 daughters of men with FXTAS demonstrated an increased incidence of neurologic and psychiatric symptoms compared to controls, providing more evidence for such an association [<xref ref-type="bibr" rid="fragilex.REF.chonchaiya.2010.38">Chonchaiya et al 2010</xref>].</p>
        <p>A male with complex <italic toggle="yes">FMR1</italic> mosaicism (full mutation, premutation, and deletion) with only learning disability [<xref ref-type="bibr" rid="fragilex.REF.han.2006.1463">Han et al 2006</xref>] also raises issues concerning gene and protein expression in <italic toggle="yes">FMR1</italic>-related phenotypes.</p>
      </sec>
      <sec id="fragilex.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Developmental delay/</bold>
<bold>intellectual disability.</bold> The signs of fragile X syndrome in early childhood are nonspecific, with developmental delay being an almost universal manifestation among affected individuals. Any child (male or female) with delay of speech, language, or motor development of unknown etiology should be considered for fragile X testing, especially in the presence of a family history of intellectual disability and a consistent physical and behavioral phenotype, and the absence of structural abnormalities of the brain or other birth defects [<xref ref-type="bibr" rid="fragilex.REF.curry.1997.468">Curry et al 1997</xref>, <xref ref-type="bibr" rid="fragilex.REF.moeschler.2006.2304">Moeschler &#x00026; Shevell 2006</xref>]. When fragile X molecular genetic testing is used regularly in this large and loosely defined group of unselected males with intellectual disability, the yield of positive test results is relatively low (~3%-6%) [<xref ref-type="bibr" rid="fragilex.REF.curry.1997.468">Curry et al 1997</xref>, <xref ref-type="bibr" rid="fragilex.REF.shevell.2003.367">Shevell et al 2003</xref>]. In a more recent study, <xref ref-type="bibr" rid="fragilex.REF.rauch.2006.2063">Rauch et al [2006]</xref> found the yield to be 1.2%.</p>
        <p>Because cytogenetic abnormalities have been identified as frequently or more frequently than <italic toggle="yes">FMR1</italic> pathogenic variants in developmentally disabled or intellectually impaired individuals referred for fragile X testing, chromosome analysis should be performed as a part of their laboratory evaluation [<xref ref-type="bibr" rid="fragilex.REF.moeschler.2006.2304">Moeschler &#x00026; Shevell 2006</xref>].</p>
        <p>Conditions to be considered in the differential diagnosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="sotos" document-type="chapter"><bold>Sotos syndrome</bold></related-object><bold>.</bold> Sotos syndrome is characterized by typical facial appearance, overgrowth, and learning disability ranging from mild to severe. It is associated with behavioral problems, congenital cardiac anomalies, neonatal jaundice, renal anomalies, scoliosis, seizures, and a slightly increased risk for sacrococcygeal teratoma and neuroblastoma. Approximately 80%-90% of individuals with Sotos syndrome have a demonstrable pathogenic variant or deletion of <italic toggle="yes">NSD1</italic>.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="pws" document-type="chapter"><bold>Prader-Willi syndrome</bold></related-object>
<bold>(PWS).</bold> A small subset of people with fragile X syndrome have the hyperphagia and obesity characteristic of PWS. PWS is characterized by severe infantile hypotonia and feeding difficulties, followed by early childhood onset of excessive eating and development of morbid obesity unless controlled. All individuals have developmental delay and cognitive impairment. Temper tantrums, stubbornness, manipulative behavior, and obsessive-compulsive characteristics are common. Hypogonadism (genital hypoplasia, incomplete puberty, and, in most, infertility), short stature, and characteristic facial appearance are common. Diagnosis is by DNA-based methylation testing to detect abnormal parent-specific imprinting within the Prader-Willi critical region on chromosome 15.</p>
          </list-item>
          <list-item>
            <p><bold>Autism.</bold> Autistic-like behavior is frequently found in individuals with fragile X syndrome.</p>
          </list-item>
          <list-item>
            <p><bold>Attention deficit-hyperactivity disorder (ADHD).</bold> Hyperactivity is frequently seen in individuals with fragile X syndrome.</p>
          </list-item>
          <list-item>
            <p><bold>Fragile XE syndrome (FRAXE).</bold> Mild intellectual disability (not as severe as that typically seen in fragile X syndrome) without consistent physical features has been described in males with expanded CCG repeats in <italic toggle="yes">FMR2</italic> at the FRAXE fragile site. FRAXA and FRAXE are distinct fragile sites, albeit in close proximity on the X chromosome. The genes spanning the two fragile sites are designated <italic toggle="yes">FMR1</italic> (FRAXA) and <italic toggle="yes">FMR2</italic> (FRAXE). However, the genes do not have any detectable similarity at the DNA level and the associated clinical entities are discrete.</p>
          </list-item>
          <list-item>
            <p><bold>Adult-onset neurologic disorders.</bold> The differential diagnosis for FXTAS is broad. One group of 56 individuals had 98 different diagnoses prior to the diagnosis of FXTAS. Most of these were in the following categories: parkinsonism, tremor, ataxia, dementia, autonomic dysfunction, and stroke [<xref ref-type="bibr" rid="fragilex.REF.biancalana.2005.962">Biancalana et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.hall.2005.299">Hall et al 2005</xref>].</p>
            <p>It is estimated that 2%-4% of men with adult-onset cerebellar ataxia who represent simplex cases (i.e., a single occurrence in a family) have a premutation in <italic toggle="yes">FMR1</italic> [<xref ref-type="bibr" rid="fragilex.REF.brussino.2005.145">Brussino et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.cellini.2006.1135">Cellini et al 2006</xref>]. See <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Hereditary Ataxia Overview</related-object>.</p>
          </list-item>
        </list>
      </sec>
      <sec id="fragilex.Management">
        <title>Management</title>
        <sec id="fragilex.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p><bold>Fragile X syndrome.</bold> To establish the extent of disease in an individual diagnosed with fragile X syndrome, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete developmental and educational assessments (including speech and language evaluation and occupational/physical therapy evaluation) for educational planning</p>
            </list-item>
            <list-item>
              <p>Behavioral and psychological assessment to determine the presence of concentration/attention problems, anxiety, obsessive-compulsive disorder, aggression, and depression</p>
            </list-item>
            <list-item>
              <p>In infants, feeding assessment (including attention to possible gastroesophageal reflux)</p>
            </list-item>
            <list-item>
              <p>Physical examination to evaluate for hypotonia and/or connective tissue findings, primarily joint hyperextensibility and pes planus</p>
            </list-item>
            <list-item>
              <p>Cardiac auscultation for mitral valve prolapse. If indicated by a murmur or click, consider echocardiography (usually in adulthood).</p>
            </list-item>
            <list-item>
              <p>Assessment for hypertension</p>
            </list-item>
            <list-item>
              <p>History for possible seizure activity</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation for possible strabismus</p>
            </list-item>
            <list-item>
              <p>In young children, history and physical examination for evidence of recurrent otitis media</p>
            </list-item>
          </list>
          <p><bold>FXTAS.</bold> To establish the extent of disease in an individual diagnosed with FXTAS, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic examination</p>
            </list-item>
            <list-item>
              <p>Behavioral and psychological assessment</p>
            </list-item>
            <list-item>
              <p>Neuroradiologic evaluation</p>
            </list-item>
          </list>
          <p><bold>POI.</bold> To establish the extent of disease in a woman diagnosed with POI, gynecologic evaluation including hormonal and/or ultrasonographic assessment is appropriate.</p>
          <p>Note: The diagnosis of POI does not eliminate the possibility of subsequent conception. A premutation carrier woman had a child with fragile X syndrome after being diagnosed with POI [<xref ref-type="bibr" rid="fragilex.REF.corrigan.2005.1508">Corrigan et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.nelson.2005.1327">Nelson et al 2005</xref>]. It is estimated that 5%-10% of women with POI may conceive after the diagnosis [<xref ref-type="bibr" rid="fragilex.REF.nelson.2005.1327">Nelson et al 2005</xref>].</p>
        </sec>
        <sec id="fragilex.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Fragile X syndrome.</bold> No specific treatment is available. Supportive therapy for children and adults with fragile X syndrome currently consists of the following [<xref ref-type="bibr" rid="fragilex.REF.hagerman.2009.378">Hagerman et al 2009</xref>, <xref ref-type="bibr" rid="fragilex.REF.utari.2010.70">Utari et al 2010</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Recognition of the need for special education and anticipatory management such as the avoidance of excessive stimulation whenever possible may ameliorate some of the behavioral difficulties.</p>
            </list-item>
            <list-item>
              <p>Early educational intervention, special education, and vocational training should be aimed specifically at the known impediments to learning. Parents and teachers of children with fragile X syndrome have recognized the need for individual attention, small class size, and the avoidance of sudden change. More specific guidelines are available through education resources (see <xref ref-type="sec" rid="fragilex.Resources">Resources</xref>).</p>
            </list-item>
            <list-item>
              <p>Pharmacologic management of behavioral issues that significantly affect social interaction is appropriate. No particular pharmacologic treatment has been shown to be uniquely beneficial; therapy must be individualized and closely monitored. A closely monitored and integrated program of behavioral management and pharmacologic treatment with an experienced developmental team may prove to be beneficial.</p>
            </list-item>
            <list-item>
              <p>Routine medical management of strabismus, otitis media, gastroesophageal reflux, seizures, mitral valve prolapse, and hypertension is appropriate.</p>
            </list-item>
          </list>
          <p><bold>FXTAS.</bold> No specific treatment is available. Supportive care for problems with gait and/or cognitive deficits may require assistance with activities of daily living.</p>
          <p><bold>POI.</bold> No specific treatment is available. Gynecologic or reproductive endocrinologic evaluation can provide appropriate treatment and counseling for reproductive options.</p>
        </sec>
        <sec id="fragilex.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Folic acid should be avoided in individuals with poorly controlled seizures [<xref ref-type="bibr" rid="fragilex.REF.hagerman.2002">Hagerman 2002</xref>].</p>
        </sec>
        <sec id="fragilex.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="fragilex.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="fragilex.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="fragilex.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="fragilex.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">FMR1</italic>-related disorders are inherited in an X-linked dominant manner.</p>
        </sec>
        <sec id="fragilex.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The mother of an individual with an <italic toggle="yes">FMR1</italic> full mutation (i.e., hypermethylated allele of &#x0003e;200 trinucleotide repeats) is a carrier of a premutation or full mutation and may be affected.</p>
            </list-item>
            <list-item>
              <p>An unaffected female premutation carrier may have a father who is a premutation carrier (i.e., a "transmitting male") or a mother who is a premutation carrier or an intermediate allele carrier.</p>
            </list-item>
            <list-item>
              <p>The mother of a male with a premutation has a premutation allele or an intermediate allele.</p>
            </list-item>
            <list-item>
              <p>Women with premutations are at risk for POI and FXTAS.</p>
            </list-item>
            <list-item>
              <p>Women with normal alleles with greater than 54 repeats may be at increased risk for POI.</p>
            </list-item>
            <list-item>
              <p>Men with premutations are at risk for FXTAS.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to sibs depends on their gender, the gender of the carrier parent, and the size of the expanded allele in the carrier parent.</p>
          <p>
            <bold>Offspring of an individual with a full mutation</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Males</bold> with a full mutation have intellectual disability and generally do not reproduce.</p>
            </list-item>
            <list-item>
              <p><bold>Females</bold> who inherit the full mutation are at an approximately 50% risk for intellectual disability. Whether or not a female has phenotypic manifestations, her offspring are at a 50% risk of inheriting the full mutation.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of an individual with a premutation</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Males</bold> who are premutation carriers are considered "transmitting males." The premutation is inherited by all of their daughters and none of their sons. When premutations are transmitted by the father, small increases in trinucleotide repeat number may occur but do not result in full mutations. (In actuality, premutations transmitted from father to daughter may often regress slightly in repeat number.) All daughters of transmitting males are unaffected premutation carriers.</p>
            </list-item>
            <list-item>
              <p><bold>Females</bold> who are premutation carriers have a 50% risk of transmitting an abnormal (premutation or full mutation) allele in each pregnancy.</p>
              <p>Very rarely, contraction of trinucleotide repeat number, such as contraction of a premutation of 110 repeats in a mother to 44 repeats in her daughter, has been reported [<xref ref-type="bibr" rid="fragilex.REF.vits.1994.523">Vits et al 1994</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>In general, the risk of a maternal premutation becoming a full mutation on transmission to her offspring is correlated with the number of CGG trinucleotide repeats in the premutation.</p>
                </list-item>
                <list-item>
                  <p>For small premutations, the interruption of the CGG repeats by occasional AGG repeats may help evaluate risk of expansion (see <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Testing">Molecular Genetic Testing</xref> and <xref ref-type="sec" rid="fragilex.Molecular_Genetics">Molecular Genetics</xref>).</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: Because most clinical laboratories do not examine the AGG repeat status and its clinical utility remains to be fully explored, risk assessment for expansion of a maternal premutation to a full mutation on transmission to offspring is nearly always based on the number of CGG trinucleotide repeats in the premutation. <xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al [2011]</xref> recently compared the risk of expanding to a full mutation relative to the size of the premutation allele (N=95). In some categories, risks were significantly different if the premutation was carried by women with a family history of fragile X. For example, maternal premutation alleles with 70-79 CGG repeats had a 54% risk for expansion if there was a family history of fragile X versus an 18% risk in the absence of a family history.</p>
          <p><bold>Offspring of an individual with an intermediate allele.</bold> About 16% of maternal transmissions of an intermediate allele may occasionally have a minor variation in repeat size (i.e., a change of 1 or 2 repeats); offspring are at negligible risk of being affected. Intermediate alleles ranging from 50 to 54 repeats may be somewhat more unstable than those with fewer than 50 repeats, and potentially may become premutation size (&#x0003e;55 repeats) [<xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al 2011</xref>]. Thus, the risk to offspring of an individual with a larger intermediate allele of inheriting a premutation allele is low but greater than that of the general population. Intermediate alleles may infrequently contract by a few repeats, and rarely by sufficiently large number of repeats to be in the normal range [<xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al 2011</xref>].</p>
          <p><bold>Other family members of a proband.</bold> The proband's maternal aunts and their offspring may be at risk of being carriers or being affected (depending on their gender and family relationship).</p>
        </sec>
        <sec id="fragilex.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing of at-risk females is possible and involves determination of the trinucleotide repeat number and the <italic toggle="yes">FMR1</italic> methylation status (see <xref ref-type="sec" rid="fragilex.Molecular_Genetics">Molecular Genetics</xref>).</p>
          <p><bold>Population-based carrier testing.</bold> Fragile X syndrome carrier screening has been offered to women not known to be at risk in the prenatal genetic counseling setting [<xref ref-type="bibr" rid="fragilex.REF.cronister.2005.246">Cronister et al 2005</xref>]. Fewer than 8% of women elected such testing. <xref ref-type="bibr" rid="fragilex.REF.anido.2005.295">Anido et al [2005]</xref> analyzed women's attitudes toward carrier testing and suggest that non-carrier women from the general population would be unprepared to learn that they are carriers.</p>
          <p>For additional information regarding population-based testing see <xref ref-type="bibr" rid="fragilex.REF.mcconkierosell.2007.593">McConkie-Rosell et al [2007]</xref>.</p>
        </sec>
        <sec id="fragilex.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Family history.</bold> The presence of premutation carriers within families leads to pedigrees with generation-skipping or seemingly spontaneous occurrences of fragile X syndrome with no previous family history of the disorder.</p>
          <p><bold>Grandchildren of transmitting males.</bold> The daughters of transmitting males are premutation carriers; thus, their offspring are at risk for fragile X syndrome.</p>
          <p><bold>Early diagnosis of fragile X syndrome.</bold> The first indication of fragile X syndrome within a family is usually the diagnosis in an affected child. A survey to assess the timing of a diagnosis in an affected child and genetic counseling for the family indicated that in approximately half of the families surveyed, the diagnosis was made more than a year after the child's development or behavior first raised concerns. Half of the surveyed families reported having subsequent pregnancies before diagnosis of the first affected child. These findings emphasize the importance of increased opportunities for early diagnosis so that children and families can receive all possible benefits, including genetic counseling and intervention services [<xref ref-type="bibr" rid="fragilex.REF.centers_for_disease_control_and_prevention_cdc_.2002.740">Centers for Disease Control and Prevention 2002</xref>].</p>
          <p><bold>Fragile X tremor ataxia syndrome (FXTAS) in males with premutation alleles.</bold> When a child is diagnosed with fragile X syndrome and his mother is found to have a premutation allele, his maternal grandfather is then known to be at risk of developing FXTAS. Premutation carrier females are also at increased risk for neurologic and psychiatric problems [<xref ref-type="bibr" rid="fragilex.REF.chonchaiya.2010.38">Chonchaiya et al 2010</xref>].</p>
          <p><bold>Primary ovarian insufficiency (POI) in females with premutation alleles.</bold> The increased risk for POI (i.e., age at menopause &#x0003c;40 years) in female premutation carriers should be taken into account when providing genetic counseling.</p>
          <p>Note: The diagnosis of POI does not eliminate the possibility of subsequent conception. A premutation carrier woman had a child with fragile X syndrome after being given the diagnosis POI [<xref ref-type="bibr" rid="fragilex.REF.corrigan.2005.1508">Corrigan et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.nelson.2005.1327">Nelson et al 2005</xref>]. It is estimated that 5%-10% of women with POI may conceive after the diagnosis [<xref ref-type="bibr" rid="fragilex.REF.nelson.2005.1327">Nelson et al 2005</xref>]. See <xref ref-type="bibr" rid="fragilex.REF.sullivan.2011.299">Sullivan et al [2011]</xref> for a review.</p>
          <p>For additional information regarding genetic counseling and cascade testing see <xref ref-type="bibr" rid="fragilex.REF.mcconkierosell.2007.593">McConkie-Rosell et al [2007]</xref>.</p>
          <p><bold>Gamete donation.</bold> Transmission of a fragile X premutation has occurred via sperm donation [<xref ref-type="bibr" rid="fragilex.REF.wirojanan.2008.888">Wirojanan et al 2008</xref>] prompting the suggestion that all egg and sperm donors have <italic toggle="yes">FMR1</italic> molecular genetic testing.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="fragilex.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>Prenatal testing for fetuses at increased risk for <italic toggle="yes">FMR1</italic> full mutations can be performed using DNA extracted from cells obtained by amniocentesis usually performed at approximately 15 to 18 weeks' gestation or CVS at approximately ten to 12 weeks' gestation (see <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Testing">Molecular Genetic Testing</xref> and <xref ref-type="sec" rid="fragilex.References">Published Guidelines/Consensus Statements</xref>). The <italic toggle="yes">FMR1</italic> Southern blot patterns for DNA derived from amniocytes are identical to those found in adult tissues; however, differences in <italic toggle="yes">FMR1</italic> methylation patterns may occur in DNA derived from cells obtained by CVS, making the distinction between large premutations and small full mutations difficult. Thus, for pregnancies evaluated by CVS, follow-up amniocentesis or testing using PCR may be necessary to determine the size of the <italic toggle="yes">FMR1</italic> alleles in a methylation-independent manner [<xref ref-type="bibr" rid="fragilex.REF.mcconkierosell.2005.249">McConkie-Rosell et al 2005</xref>].</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for families in which the pathogenic variant has been identified. Technical improvements enabling better testing of <italic toggle="yes">FMR1</italic> in single embryonic cells produced for PGD have recently been reported [<xref ref-type="bibr" rid="fragilex.REF.burlet.2006.647">Burlet et al 2006</xref>, <xref ref-type="bibr" rid="fragilex.REF.malcov.2007.515">Malcov et al 2007</xref>]. Implantation of embryos detected with normal alleles led to unaffected offspring.</p>
        </sec>
      </sec>
      <sec id="fragilex.Resources">
        <title>Resources</title>
      </sec>
      <sec id="fragilex.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="fragilex.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Nearly all <italic toggle="yes">FMR1</italic> pathogenic variants (&#x0003e;99%) resulting in fragile X syndrome occur as trinucleotide repeat (CGG) expansions accompanied by aberrant hypermethylation of the gene. Deletions and single-nucleotide variants in <italic toggle="yes">FMR1</italic> account for the remaining pathogenic variants found in individuals with the syndrome. Repeat expansion to the disease-causing range occurs only when a premutation or full mutation is transmitted by females to their offspring. Methylation of the CGG expansion results in decrease or silencing of <italic toggle="yes">FMR1</italic> transcription and loss of the protein encoded by the gene (see <bold>Abnormal gene product</bold>).</p>
          <p><xref ref-type="bibr" rid="fragilex.REF.hagerman.2001.127">Hagerman et al [2001]</xref> and <xref ref-type="bibr" rid="fragilex.REF.jacquemont.2004.460">Jacquemont et al [2004]</xref> review evidence of dysregulation of <italic toggle="yes">FMR1</italic> in the premutation range, which may explain many of the clinical observations. Paradoxically, <xref ref-type="bibr" rid="fragilex.REF.kenneson.2001.1449">Kenneson et al [2001]</xref> found a decrease in FMRP and an increase in transcription of <italic toggle="yes">FMR1</italic> in premutation carriers. These findings suggest that mRNA over-production from <italic toggle="yes">FMR1</italic> premutations may exert an effect on intracellular transport of mRNAs produced by <italic toggle="yes">FMR1</italic> and other genes. Thus, FXTAS and POI resulting from <italic toggle="yes">FMR1</italic> premutations may be manifestations of RNA-mediated toxicity [<xref ref-type="bibr" rid="fragilex.REF.galloway.2009.785">Galloway &#x00026; Nelson 2009</xref>].</p>
          <p>The mGluR theory of fragile X intellectual disability is based on the observation that activated group 1 metabotropic glutamate receptors (mGluRs) mediate long-term depression of transmission at hippocampal synapses, a process that requires translation of preexisting mRNA near synapses. Evidence strongly indicates that the FMRP represses translation of specific mRNAs. Loss of FMRP increases long-term depression of transmission at hippocampal synapses in the <italic toggle="yes">fmr-1</italic> mouse model and likely has the same effect in individuals with the fragile X syndrome. The mGluR theory of fragile X syndrome hypothesizes that in the absence of the FMRP, mGluR-dependent protein synthesis may be exaggerated and result in the fragile X syndrome phenotype [<xref ref-type="bibr" rid="fragilex.REF.bear.2004.370">Bear et al 2004</xref>].</p>
          <p><bold>Normal allelic variants.</bold>
<italic toggle="yes">FMR1</italic> occupies 38 kb of genomic DNA and has 17 exons contained in a messenger RNA of approximately 4 kb. A trinucleotide repeat, composed primarily of CGG, is contained in the untranslated portion of exon 1 ending 69 bp upstream of the translational start, near the 5' end of the gene. Variation of the repeat copy number in normal (i.e., stable) alleles ranges from five to 44 CGG repeats, with a trimodal distribution consisting of a major peak at around 30 repeats and minor peaks at around 20 and 40 repeats. Alternative splicing of <italic toggle="yes">FMR1</italic> occurs toward the 3' end of the mRNA.</p>
          <p>In most <italic toggle="yes">FMR1</italic> alleles the sequence of CGG trinucleotide repeats is interrupted by an AGG at repeat 9 or 10 and 19 or 20 (and occasionally repeat 30) [<xref ref-type="bibr" rid="fragilex.REF.eichler.1994.88">Eichler et al 1994</xref>]. These AGG repeats appear to "anchor" the segment against repeat expansion, probably by disruption of DNA secondary structures that may form during DNA replication.</p>
          <p>CGG repeat lengths in the high normal (35-44) and intermediate (45-54) ranges have been reported to be associated with POI [<xref ref-type="bibr" rid="fragilex.REF.bretherick.2005.376">Bretherick et al 2005</xref>, <xref ref-type="bibr" rid="fragilex.REF.bodega.2006.952">Bodega et al 2006</xref>] but a recent study was unable to replicate this finding [<xref ref-type="bibr" rid="fragilex.REF.bennett.2010.1335">Bennett et al 2010</xref>]. Thus, while premutation alleles clearly have an increased risk for POI, some uncertainty exists regarding alleles with fewer than 55 repeats.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Intermediate alleles.</bold> Variation of the repeat number in intermediate alleles is approximately 45-54 repeats. See <xref ref-type="sec" rid="fragilex.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>). An important predictor of repeat instability in large intermediate alleles (&#x0003e;50 repeats) is the number of "pure" CGG repeats without interrupting AGG repeats. Increasingly longer pure repeats, especially those with more than 35 uninterrupted CGG repeats, are more likely to become unstable [<xref ref-type="bibr" rid="fragilex.REF.eichler.1994.88">Eichler et al 1994</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>AGG repeats.</bold> Large increases in the number of the CGG trinucleotide repeats contained in <italic toggle="yes">FMR1</italic> occur exclusively during transmission from female carriers (see <xref ref-type="sec" rid="fragilex.Genetic_Counseling">Genetic Counseling</xref>). The risk for increase in the size of the expansion of maternal premutation alleles depends on the number of CGG repeats and the presence of AGG triplets embedded in the CGG repeat segment [<xref ref-type="bibr" rid="fragilex.REF.eichler.1994.88">Eichler et al 1994</xref>, <xref ref-type="bibr" rid="fragilex.REF.kunst.1994.853">Kunst &#x00026; Warren 1994</xref>]. Sequences of uninterrupted CGG repeats beyond the last AGG repeat ("pure CGG trinucleotide repeats") greater than approximately 33-39 triplets appear to increase the instability of maternal alleles and increase the risk for expansion of the number of trinucleotide repeats on transmission to offspring [<xref ref-type="bibr" rid="fragilex.REF.eichler.1994.88">Eichler et al 1994</xref>, <xref ref-type="bibr" rid="fragilex.REF.kunst.1994.853">Kunst &#x00026; Warren 1994</xref>]. Recent results have linked the length of the uninterrupted 3&#x02019; CGG repeat length with expansion of intermediate and small premutation alleles and suggest a minimum threshold for expansion risk [<xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al 2011</xref>]. The clinical usefulness of such testing awaits publication of the full study.</p>
            </list-item>
          </list>
          <p><bold>Pathogenic allelic variants.</bold> Newer methods promise to overcome the limitations of Southern blot analysis and greatly increase the sensitivity of PCR-based diagnosis for the full range of <italic toggle="yes">FMR1</italic> pathogenic variants [<xref ref-type="bibr" rid="fragilex.REF.chen.2010.589">Chen et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.filipovicsadic.2010.399">Filipovic-Sadic et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.hantash.2010.162">Hantash et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.lyon.2010.505">Lyon et al 2010</xref>, <xref ref-type="bibr" rid="fragilex.REF.chen.2011.528">Chen et al 2011</xref>, <xref ref-type="bibr" rid="fragilex.REF.nahhas.2012.187">Nahhas et al 2012</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Premutation <italic toggle="yes">FMR1</italic> alleles.</bold> Premutation alleles have 55-200 CGG repeats and are not hypermethylated. They do not cause fragile X syndrome in males or females. Premutation alleles often expand on maternal transmission. Expansion can result in an <italic toggle="yes">FMR1</italic> full mutation that causes fragile X syndrome in offspring; risk of expansion is dependent upon the number of CCG repeats in the mother's premutation allele. For smaller maternal premutation alleles, the number and structure of AGG trinucleotide interrupts may also affect the risk of expansion [<xref ref-type="bibr" rid="fragilex.REF.nolin.2011.925">Nolin et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Full <italic toggle="yes">FMR1</italic> expansion mutation.</bold> Expansion of the CGG repeat number beyond approximately 200, accompanied by hypermethylation of the deoxycytosine residues in the <italic toggle="yes">FMR1</italic> promoter, inhibits or reduces <italic toggle="yes">FMR1</italic> transcription, resulting in the loss of the protein product (FMRP) and giving rise to the expression of the cytogenetic fragile site, FRAXA. It is the loss of FMRP that results in the fragile X syndrome phenotype.</p>
            </list-item>
            <list-item>
              <p><bold>Rare <italic toggle="yes">FMR1</italic> variants: deletion or single-nucleotide variant.</bold> Although <italic toggle="yes">FMR1</italic> would be expected to have a mutation rate similar to other genes, there is a surprising paucity of reports of individuals with single-nucleotide variants or other small alterations in <italic toggle="yes">FMR1</italic> resulting in fragile X syndrome.</p>
              <p>Rare individuals with deletions of all or part of <italic toggle="yes">FMR1</italic> (reviewed in <xref ref-type="bibr" rid="fragilex.REF.hammond.1997.430">Hammond et al [1997]</xref>) or single-nucleotide variants in <italic toggle="yes">FMR1</italic> [<xref ref-type="bibr" rid="fragilex.REF.de_boulle.1993.31">De Boulle et al 1993</xref>, <xref ref-type="bibr" rid="fragilex.REF.lugenbeel.1995.483">Lugenbeel et al 1995</xref>, <xref ref-type="bibr" rid="fragilex.REF.wang.1997.393">Wang et al 1997</xref>] have been reported but account for far fewer than 1% of those with fragile X syndrome. The existence of affected individuals with deletions has confirmed that the syndrome is caused by the lack of <italic toggle="yes">FMR1</italic> transcription. Occasionally, an individual will appear to have no cells in which the abnormal promoter methylation events have occurred even when more than 200 CGG repeats are found. Such individuals are usually described as having "unmethylated full mutations." Individuals having partial methylation of full mutations ("methylation mosaics") are also observed. Cellular mosaicism, in which both premutation and full-mutation cell lines are present, also occurs in some individuals. (For more information, see <related-object source-id="gene" document-id="fragilex" object-id="fragilex.molgen.TA">Table A</related-object>.)</p>
            </list-item>
          </list>
          <p><bold>Normal gene product.</bold> The product of <italic toggle="yes">FMR1</italic>, fragile X mental retardation protein 1 (FMRP), is found in the cytoplasm of many cell types but is most abundant in neurons. The protein contains two KH-binding domains found in other proteins with RNA-binding properties and appears to function as an RNA-binding protein that interacts with a subset of mRNAs containing G-quartet motifs. FMRP contains both a nuclear localization signal and a nuclear export signal, suggesting that it functions as a nucleocytoplasmic shuttling protein that binds several mRNAs, including its own mRNA, forms messenger ribonucleoprotein complexes, and associates with translating ribosomes [<xref ref-type="bibr" rid="fragilex.REF.ceman.1999.7925">Ceman et al 1999</xref>]. FMRP is expressed in many tissues; it also appears to play a role in structural and functional maturation of synapses by serving as a translational suppressor in postsynaptic spaces [<xref ref-type="bibr" rid="fragilex.REF.weiler.1999.248">Weiler &#x00026; Greenough 1999</xref>]. Absence of FMRP appears to disrupt neurotransmission mediated by the metabotropic glutamate receptor (mGluR) [<xref ref-type="bibr" rid="fragilex.REF.bear.2004.370">Bear et al 2004</xref>]. Thus, FMRP likely regulates long-term depression and potentiation at neuronal synapses.</p>
          <p><bold>Abnormal gene product.</bold> It is evident from affected individuals with deletions in <italic toggle="yes">FMR1</italic> that gene loss and the consequent lack of FMRP causes fragile X syndrome. The pathogenic mechanism whereby premutation, intermediate, or high-normal alleles result in POI is not well understood. However, in contrast to the loss-of-function pathogenic variants producing fragile X syndrome, mounting evidence indicates that FXTAS results from RNA toxicity related to overexpression of premutations [<xref ref-type="bibr" rid="fragilex.REF.galloway.2009.785">Galloway &#x00026; Nelson 2009</xref>]</p>
        </sec>
      </sec>
      <sec id="fragilex.References">
        <title>References</title>
        <sec id="fragilex.Published_GuidelinesConsensus_S">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="fragilex.Published_GuidelinesConsensus_S.reflist0">
            <ref id="fragilex.REF.genetics_committee_of_the_society_of_obstetricians_and_gynaecologists_of_canada_sogc_.2008.837">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada(SOGC)</collab>
                </person-group>
                <article-title>Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists(CCMG), Chitayat D, Wyatt PR, Wilson RD, Johnson JA, Audibert F, Allen V, Gagnon A, Langlois S, Blight C, Brock JA, D&#x000e9;silets V, Farell SA, Geraghty M, Nelson T, Nikkel SM, Skidmore D, Shugar A. Fragile X testing in obstetrics and gynaecology in Canada.</article-title>
                <source>J Obstet Gynaecol Can.</source>
                <year>2008</year>
                <volume>30</volume>
                <fpage>837</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">18845054</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.kronquist.2008.845">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kronquist</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spector</surname>
                    <given-names>EB</given-names>
                  </name>
                </person-group>
                <article-title>Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines.</article-title>
                <source>Genet Med.</source>
                <year>2008</year>
                <volume>10</volume>
                <fpage>845</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18941415</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.maddalena.2001">
              <mixed-citation publication-type="web">Maddalena A, Richards CS, McGinniss MJ, Brothman A, Desnick RJ, Grier RE, Hirsch B, Jacky P, McDowell GA, Popovich B, Watson M, Wolff DJ (Quality Assurance Subcommittee of the Laboratory Practice Committee). Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the <italic toggle="yes">Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics</italic><italic toggle="yes">.</italic> 2001. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110344/">online</ext-link>. Accessed 9-28-16.</mixed-citation>
            </ref>
            <ref id="fragilex.REF.mcconkierosell.2005.249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McConkie-Rosell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finucane</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cronister</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrams</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pettersen</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Genetic counseling for fragile X syndrome: updated recommendations of the National Society of Genetic Counselors.</article-title>
                <source>J Genet Couns.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>249</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">16047089</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.sherman.2005.584">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pletcher</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driscoll</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Fragile X syndrome: diagnostic and carrier testing.</article-title>
                <source>Genet Med</source>
                <volume>7</volume>
                <fpage>584</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16247297</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.sherman.2000.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Premature ovarian failure in the fragile X syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>97</volume>
                <fpage>189</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">11449487</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.spector.2006">
              <mixed-citation publication-type="web">Spector EB, Kronquist KE. Technical standards and guidelines for fragile X testing. <italic toggle="yes">ACMG Standards and Guidelines for Clinical Genetics Laboratories</italic><italic toggle="yes">.</italic> 2006. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/Pages/ACMG_Activities/stds-2002/fx.htm">online</ext-link>. Accessed 9-28-16.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="fragilex.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="fragilex.Literature_Cited.reflist0">
            <ref id="fragilex.REF.allen.2005.435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramowitz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leslie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novak</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rusin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letz</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Examination of the effect of the polymorphic CGG repeat in the FMR1 gene on cognitive performance.</article-title>
                <source>Behav Genet</source>
                <volume>35</volume>
                <fpage>435</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">15971024</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.amos_wilson.2008.2">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amos Wilson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pratt</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phansalkar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muralidharan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Highsmith</surname>
                    <given-names>WE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridgeman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Courtney</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epp</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira-Gonzalez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjelm</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holtegaard</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jama</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakupciak</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labrousse</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richie</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roa</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohlfs</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sellers</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siegrist</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silverman</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiszniewska</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalman</surname>
                    <given-names>LV</given-names>
                  </name>
                  <collab>Fragile Xperts Working Group of the Association for Molecular Pathology Clinical Practice Committee</collab>
                </person-group>
                <year>2008</year>
                <article-title>Consensus characterization of 16 FMR1 reference materials: a consortium study.</article-title>
                <source>J Mol Diagn.</source>
                <volume>10</volume>
                <fpage>2</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">18165276</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.anido.2005.295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anido</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlson</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taft</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Women's attitudes toward testing for fragile X carrier status: a qualitative analysis.</article-title>
                <source>J Genet Couns</source>
                <volume>14</volume>
                <fpage>295</fpage>
                <lpage>306</lpage>
                <pub-id pub-id-type="pmid">16047092</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bacalman.2006.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bacalman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farzin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourgeois</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogswell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodlin-Jones</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia.</article-title>
                <source>J Clin Psychiatry</source>
                <volume>67</volume>
                <fpage>87</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">16426093</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bear.2004.370">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bear</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huber</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The mGluR theory of fragile X mental retardation.</article-title>
                <source>Trends Neurosci.</source>
                <volume>27</volume>
                <fpage>370</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15219735</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bennett.2010.1335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conway</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macperson</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobs</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure.</article-title>
                <source>Hum Reprod</source>
                <volume>25</volume>
                <fpage>1335</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20228389</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.biancalana.2005.962">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biancalana</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toft</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Ber</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tison</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherrer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thibodeau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrer</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy.</article-title>
                <source>Arch Neurol</source>
                <volume>62</volume>
                <fpage>962</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15956167</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bodega.2006.952">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bodega</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bione</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalpra</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toniolo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ornaghi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vegetti</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginelli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marozzi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation.</article-title>
                <source>Hum Reprod</source>
                <volume>21</volume>
                <fpage>952</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16361284</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bourgeois.2009.852">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bourgeois</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finucane</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A review of fragile X premutation disorders: expanding the psychiatric perspective.</article-title>
                <source>J Clin Psychiatry</source>
                <volume>70</volume>
                <fpage>852</fpage>
                <lpage>862</lpage>
                <pub-id pub-id-type="pmid">19422761</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bretherick.2005.376">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bretherick</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fluker</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>WP</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.</article-title>
                <source>Hum Genet</source>
                <volume>117</volume>
                <fpage>376</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">16078053</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.brussino.2005.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brussino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gellera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saluto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariotti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arduino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellotti</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camerlingo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Angelis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orsi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosca</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migone</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taroni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusco</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia.</article-title>
                <source>Neurology</source>
                <volume>64</volume>
                <fpage>145</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15642922</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.burlet.2006.647">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burlet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frydman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gigarel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerbrat</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tachdjian</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feyereisen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnefont</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frydman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steffann</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Multiple displacement amplification improves PGD for fragile X syndrome.</article-title>
                <source>Mol Hum Reprod</source>
                <volume>12</volume>
                <fpage>647</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16896070</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.bussani.2004.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bussani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sestini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldinotti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bucciantini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruni</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarselli</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Premature ovarian failure and fragile X premutation: a study on 45 women.</article-title>
                <source>Eur J Obstet Gynecol Reprod Biol</source>
                <volume>112</volume>
                <fpage>189</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">14746957</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.cellini.2006.1135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cellini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forleo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginestroni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nacmias</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tedde</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bagnoli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mascalchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorbi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piacentini</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Fragile X premutation with atypical symptoms at onset.</article-title>
                <source>Arch Neurol</source>
                <volume>63</volume>
                <fpage>1135</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16908740</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.ceman.1999.7925">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ceman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex.</article-title>
                <source>Mol Cell Biol</source>
                <volume>19</volume>
                <fpage>7925</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">10567518</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.centers_for_disease_control_and_prevention_cdc_.2002.740">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Centers for Disease Control and Prevention (CDC)</collab>
                </person-group>
                <article-title>Delayed diagnosis of fragile X syndrome--United States, 1990-1999.</article-title>
                <source>MMWR Morb Mortal Wkly Rep.</source>
                <year>2002</year>
                <month>Aug</month>
                <day>23</day>
                <volume>51</volume>
                <issue>33</issue>
                <fpage>740</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">12201607</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.chen.2010.589">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadd</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sah</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovic-Sadic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krosting</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekinger</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenzel</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latham</surname>
                    <given-names>GJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for Southern blot analysis.</article-title>
                <source>J Mol Diagn.</source>
                <volume>12</volume>
                <fpage>589</fpage>
                <lpage>600</lpage>
                <pub-id pub-id-type="pmid">20616364</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.chen.2011.528">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadd</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sah</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houghton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovic-Sadic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latham</surname>
                    <given-names>GJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel <italic toggle="yes">FMR1</italic> mrthylation patterns undetected in Southern blot analyses.</article-title>
                <source>Genet Med</source>
                <volume>13</volume>
                <fpage>528</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">21430544</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.chonchaiya.2010.38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chonchaiya</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>DV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Au</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lohse</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hervey</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorensen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome.</article-title>
                <source>Clin Genet</source>
                <volume>78</volume>
                <fpage>38</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">20497189</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.coffee.2009">
              <mixed-citation publication-type="book">Coffee B. Methylation-specific PCR. Curr Protoc Hum Genet. 2009;Chapter 10:Unit 10.6.</mixed-citation>
            </ref>
            <ref id="fragilex.REF.coffee.2009.503">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coffee</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keith</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albizua</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malone</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mowrey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA.</article-title>
                <source>Am J Hum Genet</source>
                <volume>85</volume>
                <fpage>503</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">19804849</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.coffey.2008.1009">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>DV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bronsky</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuhas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borodyanskaya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doerflinger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Expanded clinical phenotype of women with the FMR1 premutation.</article-title>
                <source>Am J Med Genet.</source>
                <year>2008</year>
                <volume>146A</volume>
                <fpage>1009</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">18348275</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.cohen.2006.1426">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masyn</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunberg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeCarli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogswell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loesch</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome.</article-title>
                <source>Neurology</source>
                <volume>67</volume>
                <fpage>1426</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">17060569</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.corrigan.2005.1508">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corrigan</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raygada</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanderhoof</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A woman with spontaneous premature ovarian failure gives birth to a child with fragile X syndrome.</article-title>
                <source>Fertil Steril</source>
                <volume>84</volume>
                <fpage>1508</fpage>
                <pub-id pub-id-type="pmid">16275254</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.crawford.2002.226">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meadows</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taft</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leslie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shubek</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmgreen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeargin-Allsopp</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyle</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Prevalence of the fragile X syndrome in African-Americans.</article-title>
                <source>Am J Med Genet</source>
                <volume>110</volume>
                <fpage>226</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">12116230</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.cronister.2005.246">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cronister</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMaio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahoney</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnenfeld</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallam</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Fragile X syndrome carrier screening in the prenatal genetic counseling setting.</article-title>
                <source>Genet Med</source>
                <volume>7</volume>
                <fpage>246</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">15834242</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.curry.1997.468">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Curry</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aughton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassidy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunniff</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaback</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moeschler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarleton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics.</article-title>
                <source>Am J Med Genet</source>
                <volume>72</volume>
                <fpage>468</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">9375733</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.das.1997.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubota</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daniel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovich</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosser</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arinami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledbetter</surname>
                    <given-names>DH</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Methylation analysis of the fragile X syndrome by PCR.</article-title>
                <source>Genet Test</source>
                <volume>1</volume>
                <fpage>151</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10464640</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.de_boulle.1993.31">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Boulle</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verkerk</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reyniers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vits</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendrickx</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Roy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Bos</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Graaff</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willems</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>A point mutation in the FMR-1 gene associated with fragile X mental retardation.</article-title>
                <source>Nat Genet</source>
                <volume>3</volume>
                <fpage>31</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">8490650</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.de_vries.1997.660">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Ouweland</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohkamsing</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duivenvoorden</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mol</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelsema</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Rijn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halley</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandkuijl</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tibben</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niermeijer</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group.</article-title>
                <source>Am J Hum Genet</source>
                <volume>61</volume>
                <fpage>660</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9326332</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.eichler.1994.88">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holden</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovich</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reiss</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snow</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thibodeau</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Length of uninterrupted CGG repeats determines instability in the FMR1 gene.</article-title>
                <source>Nat Genet</source>
                <volume>8</volume>
                <fpage>88</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">7987398</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.ennis.2006.253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ennis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>14</volume>
                <fpage>253</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16251893</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.farzin.2006.s137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Farzin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loesch</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacalman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.</article-title>
                <source>J Dev Behav Pediatr</source>
                <volume>27</volume>
                <fpage>S137</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">16685180</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.fernandezcarvajal.2009.306">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fernandez-Carvajal</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez Posadas</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raske</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Expansion of an FMR1 grey-zone allele to a full mutation in two generations.</article-title>
                <source>J Mol Diagn.</source>
                <volume>11</volume>
                <fpage>306</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">19525339</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.filipovicsadic.2010.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Filipovic-Sadic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sah</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krosting</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekinger</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenzel</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadd</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latham</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome.</article-title>
                <source>Clin Chem</source>
                <volume>56</volume>
                <fpage>399</fpage>
                <lpage>408</lpage>
                <pub-id pub-id-type="pmid">20056738</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.galloway.2009.785">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Galloway</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Evidence for RNA-mediated toxicity in fragile X-associated tremor/ataxia syndrome.</article-title>
                <source>Future Neurol</source>
                <volume>4</volume>
                <fpage>785</fpage>
                <pub-id pub-id-type="pmid">20161676</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.grigsby.2005">
              <mixed-citation publication-type="confproc">Grigsby J, Bennett R, Brega A, Bounds L, Cogswell J, Greco C, Hagerman P, Hagerman R, Hall D, Jacquemont S, Leehey M, Paulich M, Rice C, Rubinstein D, Tassone F. Fragile X-associated tremor-ataxia syndrome (FXTAS): An X-linked neurodegenerative phenotype. Abstract #280. Dallas, TX: American College of Medical Genetics Meeting; 2005.</mixed-citation>
            </ref>
            <ref id="fragilex.REF.grigsby.2006.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brega</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loesch</surname>
                    <given-names>DZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodrich</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogswell</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jardini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS).</article-title>
                <source>J Neurol Sci</source>
                <volume>248</volume>
                <fpage>227</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">16780889</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hagerman.2002">
              <mixed-citation publication-type="book">Hagerman RJ. Medical follow-up and pharmacotherapy. In: Hagerman RJ, Hagerman PJ, eds. <italic toggle="yes">Fragile X Syndrome: Diagnosis, Treatment, and Research</italic>. 3 ed. Baltimore, MD: The Johns Hopkins University Press; 2002:287-338.</mixed-citation>
            </ref>
            <ref id="fragilex.REF.hagerman.2009.378">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaufmann</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ono</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachiewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kronk</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delahunty</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visootak</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tranfagia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Advances in the treatment of fragile X syndrome.</article-title>
                <source>Pediatrics</source>
                <volume>123</volume>
                <fpage>378</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">19117905</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hagerman.2002.278">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The fragile X premutation: into the phenotypic fold.</article-title>
                <source>Curr Opin Genet Dev</source>
                <volume>12</volume>
                <fpage>278</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">12076670</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hagerman.2001.127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrichs</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hills</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gage</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.</article-title>
                <source>Neurology</source>
                <volume>57</volume>
                <fpage>127</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">11445641</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hall.2005.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogswell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS).</article-title>
                <source>Neurology</source>
                <volume>65</volume>
                <fpage>299</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">16043804</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hammond.1997.430">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hammond</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macias</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarleton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shashidhar Pai</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Fragile X syndrome and deletions in FMR1: new case and review of the literature.</article-title>
                <source>Am J Med Genet</source>
                <volume>72</volume>
                <fpage>430</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9375726</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.han.2006.1463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>XD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phalin</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chehab</surname>
                    <given-names>FF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mosaicism for a full mutation, premutation, and deletion of the CGG repeats results in 22% FMRP and elevated FMR1 mRNA levels in a high-functioning fragile X male.</article-title>
                <source>Am J Med Genet A</source>
                <volume>140</volume>
                <fpage>1463</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">16761284</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hantash.2010.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hantash</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goos</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buller-Burckle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peng</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarvis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <article-title>Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening.</article-title>
                <source>Genet Med.</source>
                <year>2010</year>
                <volume>12</volume>
                <fpage>162</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">20168238</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hatton.2006.1804">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hatton</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sideris</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mankowski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>DB</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirrett</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>140A</volume>
                <fpage>1804</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">16700053</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hawkins.2011.10">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elles</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Grady</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgess</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stacey</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metcalfe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Preparation and validation of the first WHO international genetic reference panel for Fragile X syndrome.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2011</year>
                <volume>19</volume>
                <fpage>10</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20736975</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hundscheid.2000.413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hundscheid</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sistermans</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braat</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straatman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiemeney</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smits</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations.</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>413</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10677300</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hunter.2009.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramowitz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rusin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry FMR1 premutation? A review of current literature.</article-title>
                <source>Genet Med</source>
                <volume>11</volume>
                <fpage>79</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">19265746</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.hunter.2008.553">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tinker</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charen</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity.</article-title>
                <source>Genet Epidemiol.</source>
                <volume>32</volume>
                <fpage>553</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18357616</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.jacquemont.2011.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birnbaum</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinbach</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biancalana</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2011</year>
                <fpage>19</fpage>
                <pub-id pub-id-type="pmid">21540884</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.jacquemont.2004.460">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunberg</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jardini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greco</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population.</article-title>
                <source>JAMA</source>
                <volume>291</volume>
                <fpage>460</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14747503</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.jacquemont.2006.804">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckett</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Size bias of fragile X premutation alleles in late-onset movement disorders.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>804</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16723388</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.kenneson.2001.1449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kenneson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagedorn</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.</article-title>
                <source>Hum Mol Genet</source>
                <volume>10</volume>
                <fpage>1449</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11448936</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.kogan.2008.859">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kogan</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornish</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study.</article-title>
                <source>Am J Med Genet B Neuropsychiatr Genet.</source>
                <volume>147B</volume>
                <fpage>859</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">18165971</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.kunst.1994.853">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kunst</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warren</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles.</article-title>
                <source>Cell</source>
                <volume>77</volume>
                <fpage>853</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">7911740</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.leehey.2008.1397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goetz</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lara</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogswell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynolds</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>FMR1 CGG repeat length predicts motor dysfunction in premutation carriers.</article-title>
                <source>Neurology</source>
                <volume>70</volume>
                <fpage>1397</fpage>
                <lpage>402</lpage>
                <pub-id pub-id-type="pmid">18057320</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.leehey.2007.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Min</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigsby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greco</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynolds</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lara</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogswell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Progression of tremor and ataxia in male carriers of the FMR1 premutation.</article-title>
                <source>Mov Disord</source>
                <volume>22</volume>
                <fpage>203</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17133502</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.loat.2006.555">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Loat</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craig</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plomin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craig</surname>
                    <given-names>IW</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Investigating the relationship between FMR1 allele length and cognitive ability in children: a subtle effect of the normal allele range on the normal ability range?</article-title>
                <source>Ann Hum Genet</source>
                <volume>70</volume>
                <fpage>555</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">16907702</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.loesch.2005.326">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Loesch</surname>
                    <given-names>DZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litewka</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brotchie</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huggins</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Magnetic resonance imaging study in older fragile X premutation male carriers.</article-title>
                <source>Ann Neurol</source>
                <volume>58</volume>
                <fpage>326</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16049924</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.louis.2006.420">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Louis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moskowitz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amaya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vonsattel</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study.</article-title>
                <source>Mov Disord</source>
                <volume>21</volume>
                <fpage>420</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16250026</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.lugenbeel.1995.483">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lugenbeel</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peier</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carson</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chudley</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>10</volume>
                <fpage>483</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">7670500</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.lyon.2010.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lyon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laver</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoccoli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marlowe</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis.</article-title>
                <source>J Mol Diagn.</source>
                <volume>12</volume>
                <fpage>505</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">20431035</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.machadoferreira_mdo.2004.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Machado-Ferreira Mdo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa-Lima</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boy</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esteves</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pimentel</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Premature ovarian failure and FRAXA premutation: Positive correlation in a Brazilian survey.</article-title>
                <source>Am J Med Genet</source>
                <volume>126A</volume>
                <fpage>237</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">15054835</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.mackenzie.2006.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacKenzie</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumargo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>A cryptic full mutation in a male with a classical fragile X phenotype.</article-title>
                <source>Clin Genet</source>
                <volume>70</volume>
                <fpage>39</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">16813602</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.maddalena.2001.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maddalena</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGinniss</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brothman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grier</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirsch</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacky</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDowell</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovich</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolff</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee.</article-title>
                <source>Genet Med</source>
                <volume>3</volume>
                <fpage>200</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11388762</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.malcov.2007.515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malcov</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naiman</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yosef</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mey-Raz</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amit</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vagman</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaron</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Preimplantation genetic diagnosis for fragile X syndrome using multiplex nested PCR.</article-title>
                <source>Reprod Biomed Online</source>
                <volume>14</volume>
                <fpage>515</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17425837</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.mcconkierosell.2005.249_1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McConkie-Rosell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finucane</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cronister</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrams</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pettersen</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.</article-title>
                <source>J Genet Couns.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>249</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">16047089</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.mcconkierosell.2007.593">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McConkie-Rosell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrams</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finucane</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cronister</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Street</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vatave</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders.</article-title>
                <source>J Genet Couns.</source>
                <year>2007</year>
                <volume>16</volume>
                <fpage>593</fpage>
                <lpage>606</lpage>
                <pub-id pub-id-type="pmid">17497108</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.moeschler.2006.2304">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moeschler</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shevell</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Clinical genetic evaluation of the child with mental retardation or developmental delays.</article-title>
                <source>Pediatrics</source>
                <volume>117</volume>
                <fpage>2304</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">16740881</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.moro.2006.713">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moro</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pisano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardina</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murgia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoccante</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darra</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battaglia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pramparo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuffardi</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerrini</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Periventricular heterotopia in fragile X syndrome.</article-title>
                <source>Neurology</source>
                <volume>67</volume>
                <fpage>713</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16924033</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.murray.1999.1217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacSwiney</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shipley</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conway</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women.</article-title>
                <source>Hum Reprod</source>
                <volume>14</volume>
                <fpage>1217</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10325264</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.nahhas.2012.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nahhas</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monroe</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botma</surname>
                    <given-names>PI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snyder</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talbott</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldman</surname>
                    <given-names>GL</given-names>
                  </name>
                </person-group>
                <article-title>Evaluation of the human fragile X mental retardation 1 polymerase chain reaction reagents to amplify the FMR1 gene: testing in a clinical diagnostic laboratory.</article-title>
                <source>Genet Test Mol Biomarkers.</source>
                <year>2012</year>
                <volume>16</volume>
                <fpage>187</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">21992462</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.nelson.2005.1327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Covington</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebar</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>An update: spontaneous premature ovarian failure is not an early menopause.</article-title>
                <source>Fertil Steril</source>
                <volume>83</volume>
                <fpage>1327</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15866564</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.nolin.2011.925">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nolin</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glicksman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ersalesi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>WT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobkin</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Fragile X analysis of 1112 prenatal samples from 1991 to 2010.</article-title>
                <source>Prenat Diagn.</source>
                <year>2011</year>
                <volume>31</volume>
                <fpage>925</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">21717484</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.nygren.2008.496">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nygren</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lens</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carvalho</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Methylation-specific multiplex ligation-dependent probe amplification enables a rapid and reliable distinction between male FMR1 premutation and full-mutation alleles.</article-title>
                <source>J Mol Diagn</source>
                <volume>10</volume>
                <fpage>496</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">18832455</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.orrico.1998.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orrico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dotti</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plewnia</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Censini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federico</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mosaicism for full mutation and normal-sized allele of the FMR1 gene: a new case.</article-title>
                <source>Am J Med Genet</source>
                <volume>78</volume>
                <fpage>341</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9714436</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.rauch.2006.2063">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rauch</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guth</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zweier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraus</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zenker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000fc;ffmeier</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000fc;schendorf</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trautmann</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>140</volume>
                <fpage>2063</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">16917849</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.riddle.1998.590">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riddle</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheema</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobesky</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pennington</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Phenotypic involvement in females with the FMR1 gene mutation.</article-title>
                <source>Am J Ment Retard</source>
                <volume>102</volume>
                <fpage>590</fpage>
                <lpage>601</lpage>
                <pub-id pub-id-type="pmid">9606468</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.rodriguezrevenga.2009.1359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodriguez-Revenga</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madrigal</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagonabarraga</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xuncl&#x000e0;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badenas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulisevsky</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mil&#x000e0;</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>17</volume>
                <fpage>1359</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">19367323</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.rousseau.1995.1006">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rousseau</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouillard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morel</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khandjian</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Prevalence of carriers of premutation-size alleles of the FMRI gene - and implications for the population genetics of the fragile X syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>57</volume>
                <fpage>1006</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">7485149</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.schmucker.1999.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schmucker</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidel</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Mosaicism for a full mutation and a normal size allele in two fragile X males.</article-title>
                <source>Am J Med Genet</source>
                <volume>84</volume>
                <fpage>221</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10331596</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.sherman.2005">
              <mixed-citation publication-type="confproc">Sherman S (2005) Clinical implications of gray-zone FMR1 alleles. Abstract #308. Dallas, TX: American College of Medical Genetics Meeting; 2005.</mixed-citation>
            </ref>
            <ref id="fragilex.REF.sherman.2005.584_1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pletcher</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driscoll</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Fragile X syndrome: diagnostic and carrier testing.</article-title>
                <source>Genet Med.</source>
                <year>2005</year>
                <volume>7</volume>
                <fpage>584</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16247297</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.shevell.2003.367">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shevell</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashwal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donley</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flint</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gingold</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirtz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majnemer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noetzel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheth</surname>
                    <given-names>RD</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society.</article-title>
                <source>Neurology</source>
                <volume>60</volume>
                <fpage>367</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">12578916</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.strom.2007.46">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crossley</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redman</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buller</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peng</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGinnis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenwick</surname>
                    <given-names>RG</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Molecular testing for Fragile X Syndrome: lessons learned from 119,232 tests performed in a clinical laboratory.</article-title>
                <source>Genet Med</source>
                <volume>9</volume>
                <fpage>46</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">17224689</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.sullivan.2005.402">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcus</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anido</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paquin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yadav-Shah</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Association of FMR1 repeat size with ovarian dysfunction.</article-title>
                <source>Hum Reprod</source>
                <volume>20</volume>
                <fpage>402</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">15608041</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.sullivan.2011.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welt</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>FMR1 and the continuum of primary ovarian insufficiency.</article-title>
                <source>Semin Reprod Med.</source>
                <volume>29</volume>
                <fpage>299</fpage>
                <lpage>307</lpage>
                <pub-id pub-id-type="pmid">21969264</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.tarleton.1993.169">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tarleton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saul</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Molecular genetic advances in fragile X syndrome.</article-title>
                <source>J Pediatr</source>
                <volume>122</volume>
                <fpage>169</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">8429429</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.tassone.2007.566">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusco</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS).</article-title>
                <source>Am J Med Genet B Neuropsychiatr Genet</source>
                <volume>144B</volume>
                <fpage>566</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17427188</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.tassone.1999.250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikle</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyer</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lampe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>AK</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>FMRP expression as a potential prognostic indicator in fragile X syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>84</volume>
                <fpage>250</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">10331602</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.toledanoalhadef.2001.351">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Toledano-Alhadef</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basel-Vanagaite</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magal</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidov</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrlich</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drasinover</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taub</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halpern</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginott</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shohat</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Fragile-X carrier screening and the prevalence of premutation and full- mutation carriers in Israel.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69</volume>
                <fpage>351</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">11443541</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.tzeng.2005.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tzeng</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chao</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jong</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chao</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>133A</volume>
                <fpage>37</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">15637705</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.utari.2010.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Utari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry-Kravis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chavez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaggs</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngotran</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Aging in the fragile X syndrome.</article-title>
                <source>J Neurodev Disord.</source>
                <volume>2</volume>
                <fpage>70</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20585378</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.uzielli.1999.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Uzielli</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guarducci</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecconi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricotti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biondi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarselli</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarnato</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gori</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sereni</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data.</article-title>
                <source>Am J Med Genet</source>
                <volume>84</volume>
                <fpage>300</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10331612</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.vits.1994.523">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vits</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Boulle</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reyniers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Handig</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darby</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willems</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Apparent regression of the CGG repeat in FMR1 to an allele of normal size.</article-title>
                <source>Hum Genet</source>
                <volume>94</volume>
                <fpage>523</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">7959688</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.wang.1997.393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>SY</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Novel point mutation within intron 10 of FMR-1 gene causing fragile X syndrome</article-title>
                <source>Hum Mutat</source>
                <volume>10</volume>
                <fpage>393</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9375856</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.weiler.1999.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weiler</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenough</surname>
                    <given-names>WT</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Synaptic synthesis of the Fragile X protein: possible involvement in synapse maturation and elimination.</article-title>
                <source>Am J Med Genet</source>
                <volume>83</volume>
                <fpage>248</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">10208156</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.weinh_usel.2001.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinh&#x000e4;usel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>OA</given-names>
                  </name>
                </person-group>
                <article-title>Evaluation of the fragile X (FRAXA) syndrome with methylation-sensitive PCR.</article-title>
                <source>Hum Genet.</source>
                <year>2001</year>
                <volume>108</volume>
                <fpage>450</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11499669</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.willemsen.1997.308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smits</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohkamsing</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Beerendonk</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Haan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Ouweland</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sistermans</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galjaard</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Rapid antibody test for diagnosing fragile X syndrome: a validation of the technique.</article-title>
                <source>Hum Genet</source>
                <volume>99</volume>
                <fpage>308</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">9050914</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.wirojanan.2008.888">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wirojanan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angkustsiri</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassone</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>A girl with fragile X premutation from sperm donation.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2008</year>
                <volume>146A</volume>
                <fpage>888</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">18286596</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.wittenberger.2007.456">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wittenberger</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McConkie-Rosell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welt</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebar</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corrigan</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The FMR1 premutation and reproduction.</article-title>
                <source>Fertil Steril</source>
                <volume>87</volume>
                <fpage>456</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">17074338</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="fragilex.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="fragilex.Suggested_Reading.reflist0">
            <ref id="fragilex.REF.chonchaiya.2009.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chonchaiya</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Fragile X: a family of disorders.</article-title>
                <source>Adv Pediatr</source>
                <volume>56</volume>
                <fpage>165</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">19968948</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.dhulst.2009.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D'Hulst</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kooy</surname>
                    <given-names>RF</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Fragile X syndrome: from molecular genetics to therapy.</article-title>
                <source>J Med Genet</source>
                <volume>46</volume>
                <fpage>577</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">19724010</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.jacquemont.2007.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacquemont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagerman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leehey</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.</article-title>
                <source>Lancet Neurol</source>
                <volume>6</volume>
                <fpage>45</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">17166801</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.koukoui.2007.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koukoui</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaudhuri</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome.</article-title>
                <source>Brain Res Rev</source>
                <volume>53</volume>
                <fpage>27</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">16844227</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.ribeiro.2010.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paquet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cregan</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferguson</surname>
                    <given-names>SS</given-names>
                  </name>
                </person-group>
                <article-title>Group I metabotropic glutamate receptor signalling and its implication in neurological disease.</article-title>
                <source>CNS Neurol Disord Drug Targets.</source>
                <year>2010</year>
                <month>Nov</month>
                <volume>9</volume>
                <issue>5</issue>
                <fpage>574</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">20632969</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.tejada.2008.945">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tejada</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Alegr&#x000ed;a</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilbao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez-Bouzas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beristain</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos-Arroyo</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f3;pez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez Carvajal</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribate</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome.</article-title>
                <source>Menopause</source>
                <volume>15</volume>
                <fpage>945</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18427356</pub-id>
              </element-citation>
            </ref>
            <ref id="fragilex.REF.warren">
              <mixed-citation publication-type="book">Warren ST, Sherman SL. The fragile X syndrome. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chapter 64. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="fragilex.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="fragilex.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 April 2012 (rs/jt) Revision: clarification in Clinical Diagnosis and Natural History sections</p>
            </list-item>
            <list-item>
              <p>26 January 2012 (cd) Revision: AGG genotyping as a discrete test to determine number and location of AGG interruptions with CGG repeats in <italic toggle="yes">FMR1</italic> listed in GeneTests&#x02122; Laboratory Directory; findings re POI reported in 16 June 2011 revision confirmed; new data on risk for intermediate and premutation allele expansion when a family history of fragile X syndrome is present</p>
            </list-item>
            <list-item>
              <p>16 June 2011 (cd) Revision: repeats in the high-normal range found not to predispose to POI [<xref ref-type="bibr" rid="fragilex.REF.bennett.2010.1335">Bennett et al 2010</xref>]</p>
            </list-item>
            <list-item>
              <p>28 October 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 August 2008 (cd) Revision: deletion/duplication testing available clinically</p>
            </list-item>
            <list-item>
              <p>7 March 2008 (cd) Revision: FISH analysis available clinically</p>
            </list-item>
            <list-item>
              <p>20 December 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>15 March 2007 (cd) Revision: correction of the wording and the discrepancy associated with only using premutation when gray zone (AKA intermediate) <italic toggle="yes">FMR1</italic> alleles also present increased risk</p>
            </list-item>
            <list-item>
              <p>25 April 2006 (bp) Revision: <xref ref-type="table" rid="fragilex.T.types_of_fmr1_repeat_expansio">Table 4</xref> updated according to Nolin et al (2003)</p>
            </list-item>
            <list-item>
              <p>1 March 2006 (cd) Revision: updated ACMG practice guideline</p>
            </list-item>
            <list-item>
              <p>2 December 2005 (jt) Revision: sequence analysis of <italic toggle="yes">FMR1</italic> clinically available; updated genetic counseling recommendations</p>
            </list-item>
            <list-item>
              <p>24 May 2005 (rs/jt) Comprehensive update: change in scope of GeneReview from fragile X syndrome to <italic toggle="yes">FMR1</italic>-related disorders</p>
            </list-item>
            <list-item>
              <p>13 September 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>20 April 2004 (jt) Revisions: Testing Algorithm; FXTAS</p>
            </list-item>
            <list-item>
              <p>22 November 2002 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>26 May 2000 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 June 1998 (pb) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>May 1996 (jt) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="fragilex.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Testing algorithm for <italic toggle="yes">FMR1</italic>-related disorders. The boxes marked with asterisks (*) identify individuals to be considered for <italic toggle="yes">FMR1</italic> molecular testing. See <xref ref-type="sec" rid="fragilex.Testing_Strategy">Testing Strategy</xref>, Confirming/establishing the diagnosis in a proband for further discussion [<xref ref-type="bibr" rid="fragilex.REF.maddalena.2001">Maddalena et al 2001</xref>, <xref ref-type="bibr" rid="fragilex.REF.sherman.2005.584">Sherman et al 2005</xref>].</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fragilex-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
